
==== Front
Cell Mol Life Sci
Cell Mol Life Sci
Cellular and Molecular Life Sciences: CMLS
1420-682X
1420-9071
Springer International Publishing Cham

39223418
5419
10.1007/s00018-024-05419-5
Review
Lysosomal dysfunction in α-synuclein pathology: molecular mechanisms and therapeutic strategies
http://orcid.org/0000-0003-1851-9380
Dai Lijun 1
Liu Miao 1
Ke Wei 1
Chen Liam 2
Fang Xin fangx2011@163.com

3
http://orcid.org/0000-0001-6708-1472
Zhang Zhentao Zhentaozhang@whu.edu.cn

14
1 https://ror.org/03ekhbz91 grid.412632.0 0000 0004 1758 2270 Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060 China
2 grid.17635.36 0000000419368657 Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, MN USA
3 https://ror.org/05gbwr869 grid.412604.5 0000 0004 1758 4073 Department of Neurology, the First Affiliated Hospital of Nanchang University, Nanchang, 330000 China
4 https://ror.org/033vjfk17 grid.49470.3e 0000 0001 2331 6153 TaiKang Center for Life and Medical Science, Wuhan University, Wuhan, 430000 China
3 9 2024
3 9 2024
12 2024
81 1 38215 5 2024
9 8 2024
19 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
In orchestrating cell signaling, facilitating plasma membrane repair, supervising protein secretion, managing waste elimination, and regulating energy consumption, lysosomes are indispensable guardians that play a crucial role in preserving intracellular homeostasis. Neurons are terminally differentiated post-mitotic cells. Neuronal function and waste elimination depend on normal lysosomal function. Converging data suggest that lysosomal dysfunction is a critical event in the etiology of Parkinson’s disease (PD). Mutations in Glucosylceramidase Beta 1 (GBA1) and leucine-rich repeat kinase 2 (LRRK2) confer an increased risk for the development of parkinsonism. Furthermore, lysosomal dysfunction has been observed in the affected neurons of sporadic PD (sPD) patients. Given that lysosomal hydrolases actively contribute to the breakdown of impaired organelles and misfolded proteins, any compromise in lysosomal integrity could incite abnormal accumulation of proteins, including α-synuclein, the major component of Lewy bodies in PD. Clinical observations have shown that lysosomal protein levels in cerebrospinal fluid may serve as potential biomarkers for PD diagnosis and as signs of lysosomal dysfunction. In this review, we summarize the current evidence regarding lysosomal dysfunction in PD and discuss the intimate relationship between lysosomal dysfunction and pathological α-synuclein. In addition, we discuss therapeutic strategies that target lysosomes to treat PD.

Keywords

Chaperone-mediated autophagy
GBA1
TMEM175
Therapeutic strategies
Biomarkers
http://dx.doi.org/10.13039/501100001809 National Natural Science Foundation of China 82271447 823B2026 Dai Lijun Zhang Zhentao the Innovative Research Groups of Hubei Province2022CFA026 Zhang Zhentao http://dx.doi.org/10.13039/501100012166 National Key Research and Development Program of China 2019YFE0115900 Zhang Zhentao Project for Academic and Technical Leaders of Major Disciplines in Jiangxi Province20213BCJL22049 Fang Xin issue-copyright-statement© Springer Nature Switzerland AG 2024
==== Body
pmcIntroduction

Parkinson’s disease (PD) is a neurodegenerative disease characterized by the death of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the formation of axonal and intracytoplasmic inclusions [1]. The intracytoplasmic inclusions are known as Lewy neurites (LNs) and Lewy bodies (LBs), which mainly consist of abnormally aggregated α-synuclein (α-syn) [1]. The etiology of PD has not been fully elucidated but is thought to be multifactorial. Both environmental and genetic factors contribute to the onset and progression of PD [1]. Recent evidence has shown that lysosomal dysfunction plays a central role in PD pathogenesis [2–4].

Lysosomes, vesicular structures integral to cellular metabolism, play pivotal roles in the degradation and recycling of diverse organelles and intricate molecules [5]. Additionally, they actively contribute to various cellular processes, including cytomembrane repair and the maintenance of cholesterol homeostasis [5]. Neurons, postmitotic cells that cannot divide, heavily depend on the ability of lysosomes to prevent the accumulation of aberrant proteins and impaired organelles within their cellular milieu [6]. Lysosomal dysfunction leads to massive accumulations of proteins, lipids and damaged organelles [6]. The functions of the lysosome are regulated by multiple factors, including luminal pH and proteolytic enzyme activity [5]. Lysosomal dysfunction is implicated in the pathogenesis of neurodegenerative diseases such as PD, frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The nuances and shared characteristics of lysosomal dysfunction in PD and other neurodegenerative disorders have been meticulously described in prior reviews [4, 6]. Moreover, lysosomal enzymes and proteins can be detected in cerebrospinal fluid (CSF), and they may reflect the disease state and hold promise as diagnostic biomarkers for PD [7]. Within this review, we present substantiated evidence delineating lysosomal dysfunction in PD and delve into its correlation with α-syn pathology. We also discuss the possibility of using lysosomal proteins as diagnostic biomarkers for PD. Furthermore, we summarize potential lysosomal-targeting compounds as therapeutic strategies for PD.

The physiological function of the lysosomal system

The physiological functions and intricate composition of lysosomes have been comprehensively summarized in several recent reviews [8, 9]. Lysosomes are membrane-bound organelles that contain a variety of hydrolytic enzymes responsible for the degradation and recycling of macromolecules, including proteins, lipids, carbohydrates, and nucleic acids [8]. They play a pivotal role in (1) intracellular digestion: lysosomes breakdown endocytosed materials, cellular debris, and damaged organelles, ensuring the efficient turnover of cellular components; (2) autophagy; (3) maintenance of cellular homeostasis by regulating the turnover of biomolecules, lysosomes contribute to maintaining cellular homeostasis and energy balance; (4) regulation of cellular signaling: lysosomal enzymes and their activity influence various cellular signaling pathways, including those involved in growth, stress responses, and apoptosis; and (5) metal ion homeostasis: lysosomes help regulate the intracellular concentration of metal ions such as iron and copper, which is crucial for numerous enzymatic and structural functions within the cell [8]. Lysosomes, recognized as the ultimate terminals for the degradation of both intracellular and exogenous cargo, receive substrates through two principal pathways. Extracellular elements enter lysosomes via endocytosis, a process initiated at the plasma membrane, culminating in the formation of endocytic vesicles laden with cargo molecules [8]. Moreover, intracellular substances enter lysosomes through various autophagic pathways. These pathways, comprising macroautophagy, chaperone-mediated autophagy (CMA), and microautophagy, delineate distinct mechanisms orchestrating the targeted delivery of cellular constituents to the lysosomal degradative machinery [2, 10]. In the realm of microautophagy, lysosomes engulf cytosolic proteins by invaginating either endosomal or lysosomal membranes. Chaperone-mediated autophagy (CMA) is a precision-driven process that selectively targets cytoplasmic proteins bearing a distinctive recognition motif. This motif is duly acknowledged and bound by the cytoplasmic companion protein heat shock cognate protein 70 (Hsc70) and serves as the gateway for the trafficking of these proteins to lysosomes. Facilitated by interactions with the membrane protein LAMP2A, these complexes undergo transport to the lysosomal realm. In stark contrast, macroautophagy, the most prevalent form of autophagy, involves the biogenesis of autophagic vesicles (AVs) and is characterized by the presence of double membrane-bound organelles known as autophagosomes [10, 11]. This paper focuses primarily on therapeutic targets and lysosomal dysfunction in PD. For an in-depth discussion of the physiological functions of lysosomes, readers are directed to previous reviews [8, 9].

Converging evidence for a role of lysosome dysfunction in PD

Evidence of lysosomal dysfunction in PD has been extensively documented, encompassing several key aspects: (1) structural abnormalities of lysosomes, (2) alterations in lysosomal hydrolase activity, (3) genetic factors, and (4) the accumulation of α-syn [4, 12–14]. Autopsy studies of patients with sporadic PD have revealed significant structural abnormalities within lysosomes, including changes in their size, shape, and number in dopaminergic neurons [15]. Immunoreactivity for lysosome-associated membrane protein 1 (LAMP1), cathepsin D (CTSD), and heat shock protein 73 (HSP73) is significantly lower in the nigral neurons of PD patients than in those of age-matched controls [15]. Electron microscopy has revealed swollen and fragmented lysosomes, indicative of impaired lysosomal function [16]. We provide a detailed description of genetic factors, alterations in lysosomal activity, and α-syn accumulation during lysosomal dysfunction.

Genetic evidence

Mutations in lysosome-related genes play pivotal roles in the onset of PD. A summary of the gene mutations associated with PD is provided in Table 1. A comprehensive review systematically examined and detailed the intricate relationships between lysosomal genes and PD [12].Table 1 Pathogenic mutations in lysosomal genes involved in PD

Gene	Protein	Function	Proposed mechanism	Findings in PD model	
GBA1	Glucocerebrosidase	Hydrolysis of GlcCer	Loss-of-function (enzymatic deficiency)	Mitochondrial dysfunction [156]

ER stress [157]

Calcium homeostasis dysregulation [11, 18]

GlcCer accumulation and α-syn aggregation[26, 28, 78, 158]

	
LRRK2	Leucine rich repeat kinase 2	Recruitment to lysosome and phosphorylation of Rab proteins	Gain-of-function (increased kinase activity)	Alterations in the regulation of macroautophagy [159]

Impaired lysosomal function with abnormal lysosomal morphology and increased alkalinization [160]

Impaired CMA by enhanced binding to LAMP2A and blockage of degradation of other CMA substrates including α-syn [161]

α-syn accumulation and oligomerization[162]

	
TMEM175	Transmembrane protein 175	Lysosomal K+ channel	Loss-of-function	α-syn aggregates accumulation [44]

Reduced activity of GCase [47]

	
ATP13A2	ATPase cation transporting 13A2	Exporter of polyamines such as spermine	Loss-of-function	Impaired lysosomal acidification [55]

Decreased lysosomal-mediated clearance of autophagosomes

Deficiency of lysosomal enzymes

Lysosomal substrates accumulation

	
ATP10B	ATPase phospholipid transporting 10B	Flippase of GlcCer/PC	Loss-of-function	Impaired ATPase activity, GluCer and PC translocation activity and lysosomal function [13, 163]	
VPS35	Vacuolar protein sorting-associated protein 35	Role in endosome–Golgi complex trafficking	Loss-of-function	Increased Aβ, elevated β-secretase activity, synaptic dysfunctions, and memory deficits [66]

α-syn accumulation, degeneration of dopaminergic neurons, locomotor behavior impairment, alteration of lysosomal morphology [65]

	

GBA1

Glucosylceramidase beta 1 (GBA1) is the most common gene associated with familial PD. Patients with Gaucher disease (GC) or carriers of GBA1 mutations are more likely to develop PD, multiple system atrophy (MSA), or dementia with Lewy bodies (DLB) [17]. Current evidence indicates that GBA1-associated PD involves multiple dysfunctions, including mitochondrial dysfunction, ER stress, aberrant processing of abnormal or misfolded proteins, disruption of the autophagy‒lysosome system, and dysregulation of calcium homeostasis [11, 18]. GBA1-associated PD is characterized by a more severe clinical course, earlier onset, greater incidence of nonmotor and cognitive symptoms, and earlier age of death than sPD [19, 20]. Interestingly, the pattern of dopaminergic neuronal loss in PD patients is similar to that in sPD patients [21]. Intriguingly, both pathogenic (e.g., N370S, D496H, L444P) and benign (e.g., T369M, E326K) variants of the GBA1 gene have been identified within the spectrum of PD, adding a layer of complexity to the genetic landscape associated with this neurodegenerative disorder [22].

The GBA1 gene encodes lysosomal acid β-glucocerebrosidase (GCase), which hydrolyzes lysosomal glucosylceramide (GlcCer) [23]. After translation on ribosomes, GCase undergoes four N-linked glycosylations (Asn309, Asp 185, Asn98, and Asn58) at the endoplasmic reticulum (ER). Glycosylation is conducive to chaperone-mediated folding of GCases in the ER [19]. After accurate folding, GCase is transported into the Golgi network (TGN), where it can undergo N-glycan modification. Mature GCase is subsequently transported to lysosomes. In lysosomes, saposin C determines the activity of GCase.

GBA1 mutations are also closely associated with α-syn aggregation [18, 20, 22, 24]. α-Syn is primarily localized to presynaptic nerve terminals. It accumulates abnormally and aggregates under pathological conditions. Studies indicate the accumulation of α-syn within GBA1-related PD patients [19]. Intriguingly, this accumulation impedes the trafficking of GCase from the endoplasmic reticulum (ER) to lysosomes [25]. Furthermore, mutant forms of GCase exacerbate the aggregation of α-syn, contributing to the intricate interplay between lysosomal dysfunction and α-syn pathology in the context of GBA1-related PD [26]. An increase in α-syn levels is observed in Mesencephalic MES23.5 cells overexpressing mutant GCase [27]. Mutant GCase also increases the half-life of α-syn in vivo and in vitro [27]. Furthermore, chaperone-mediated autophagy is impaired in the presence of mutant GCase [11, 18]. The increased half-life of α-syn and impaired autophagy cause α-syn accumulation. Furthermore, a GCase inhibitor induces GlcCer accumulation and α-syn aggregation and accumulation [26, 28].

LRRK2

Leucine-rich repeat kinase 2 (LRRK2) is a 2527-amino acid protein with two enzymatic domains, namely, a serine/threonine kinase domain and a Ras-of-complex (ROC) C-terminal of the Roc domain (COR) (ROC-COR) GTPase domain [29]. The most frequent autosomal dominant monogenic PD is caused by mutations in LRRK2. LRRK2 variants are involved in both familial PD and sPD [30–32]. However, the pathogenesis of LRRK2 is unclear. The most common pathogenic mutations are R1441G/C/H and Y1669C in the ROC-COR GTPase domain and I2020T and G2019S in the kinase domain. Foremost among these variants is G2019S, which is the most prevalent variant, constituting 4% of familial PD cases and 1% of sPD cases on a global scale [29]. These pathogenic mutations all result in elevated kinase activity.

LRRK2 is involved in numerous cellular processes, including various types of autophagy, such as macroautophagy and mitophagy; endocytosis; intracellular transport involving the trans-Golgi network (TGN) and other organelles; the regulation of microtubules; interactions with bacterial pathogens; and the maintenance of lysosomal homeostasis, among other functions [33]. Interestingly, LRRK2 is recruited to impair lysosomes, a process that is exacerbated by PD-related LRRK2 mutations [32]. However, the mechanism and results of LRRK2 recruitment to lysosomes are unclear [34]. Important evidence for the physiological role of LRRK2 in regulating autophagy comes from knockout animal studies. Specifically, in LRRK2 knockout kidneys, there is an accumulation of lipofuscin granules, aggregated α-synuclein, and increased levels of the autophagosomal marker LC3-II [35]. These effects are age dependent, showing biphasic alterations in autophagy: an initial increase in p62 and LC3-II at 7 months, followed by a decrease at 20 months. However, no changes in LC3-II were observed in an independent study of the kidneys of 14-month-old LRRK2 knockout mice [36]. Under conditions that stimulate autophagy but inhibit lysosomal fusion, LRRK2 knockdown results in a reduced accumulation of autophagosomes [37]. Furthermore, inhibition of LRRK2 kinase activity has been demonstrated to increase the levels of the lipidated autophagosome marker LC3-II and the adaptor protein p62 [38]. Recent studies have shown that this kinase-dependent regulation of LC3 lipidation operates through Beclin-1 signaling and is independent of mTOR/ULK1 signaling, indicating a non-canonical pathway for autophagy regulation [39]. Moreover, elevated levels of lysosomal markers and the lysosomal protease cathepsin D have been observed in the kidneys of LRRK2 knockout mice compared with their wild-type counterparts, regardless of age [40]. These findings demonstrate a close relationship between LRRK2 and lysosomal function. Studies have shown that LRRK2 is involved in the transport and formation of endosomes [41, 42]. Early endosomes are the primary step in the endolysosomal pathway. Rab GTPases bind to membranes and utilize their guanine nucleotide-binding status to form specific functional domains on their corresponding organelle membranes, thus earning the title of master regulators of intracellular vesicular trafficking [33]. LRRK2 appears to regulate lysosomal function through its kinase activity on a subset of Rab GTPases, which have been confirmed as bona fide substrates of LRRK2 [43]. Upon lysosomal stress, LRRK2 is recruited from the cytoplasm to enlarged lysosomes by Rab7L1 (also known as Rab29) [43]. Moreover, Rab8a and Rab10 accumulate in LRRK2-positive enlarged lysosomes in an LRRK2 kinase-dependent manner [43]. This sequential recruitment of Rab7L1, LRRK2, phosphorylated Rab8a, and Rab10 to lysosomes under stress conditions suppresses lysosomal enlargement and promotes the release of lysosomal contents, highlighting the role of the Rab7L1‒LRRK2 pathway in maintaining lysosome homeostasis [43]. Disruption of early endosome maturation or transport to late endosomes may affect overall lysosomal function. Swollen Rab5-positive early endosomes accumulate in SN dopaminergic neurons during disease progression [42]. Interestingly, LRRK2 colocalizes with early endosome antigen 1 (EEA1)-positive early endosomes [31]. Blockade of LRRK2 activity with PF-360 inhibited the accumulation of Rab5-positive early endosomes in a mouse model of PD [32]. Moreover, Rab5b, but not Rab5a, is viewed as a potential substrate for LRRK2 in overexpression studies. These observations indicate that the increase in LRRK2 kinase activity may be responsible for the accumulation of Rab5-positive endosomes [30]. In the endolysosomal pathway, newly internalized cargo from the cytomembrane is rapidly targeted to Rab5-positive early endosomes, after which the early endosome eventually matures into a Rab7-positive late endosome where the luminal pH of the endosome is gradually reduced. Given that degrading or recycling endosomes are regulated by various Rab GTPases and that a series of these Rab GTPases are substrates of LRRK2, LRRK2 is thought to regulate the endolysosomal pathway. Elevated LRRK2 kinase activity results in the accumulation of Rab5-positive early endosomes and ultimately causes fewer Rab7-positive late endosomes. Endolysosomal dysfunction in turn exacerbates LRRK2 activity, creating a vicious cycle.

TMEM175

As a lysosomal potassium channel, transmembrane protein 175 (TMEM175) participates in the regulation of lysosomal pH and autophagy [44]. Multiple genome-wide association studies (GWASs) of PD have identified both risk and protective variants of TMEM175 [45, 46]. The TMEM175 p.M393T (rs34311866) variant is the most significant risk factor for PD, whereas the TMEM175 p.Q65P (rs34884217) variant is a protective factor [46]. The risk variant p.M393T likely destabilizes the hydrophobic core of one TM domain, therefore damaging its folding and activity in the lysosome [44]. The protective variant p.Q65P potentially elevates K+ conductance, thus potentially promoting lysosomal function [47]. TMEM175 has been identified as a K⁺ channel that mediates potassium conductance across lysosomal and endosomal membranes, thereby regulating both lysosomal membrane potential and pH [48]. In the p.Q65P variant, a mutation occurs at the first codon of the fourth exon, which stabilizes the ion-selective portion of the structural domain. This modification enhances the permeability of the TMEM175 channel to potassium ions, thereby exerting a protective effect [47]. Moreover, lysosomes lacking TMEM175 exhibit decreased luminal pH stability and potassium conductance [49]. A reduction in TMEM175 leads to increased accumulation of hyperphosphorylated α-syn aggregates induced by α-syn preformed fibrils (α-syn PFFs), whereas TMEM175 overexpression reduces α-syn PFF-induced inclusions[44]. Primary hippocampal neurons were treated with AAV-TMEM175 and then incubated with α-syn PFFs for 14 days. The results showed that TMEM175 overexpression reduced α-syn PFF-induced inclusions. Furthermore, genetic removal of TMEM175 also results in reduced activity of GCase in cellular models due to altered lysosomal pH [47]. Moreover, decreased GCase activity may result in increased α-syn cell-to-cell transmission, as well as reduced chaperone-mediated autophagy, all of which potentially contribute to PD pathogenesis. The roles of TMEM175 and PD have been summarized in a previous review [50].

ATP13A2

Studies have shown that ATPase cation transporting 13A2 (ATP13A2) mRNA levels are highest in the substantia nigra and lowest in the cerebellum [51, 52]. Moreover, compared with those in postmortem healthy brains, ATP13A2 levels are significantly elevated in human SN dopaminergic neurons from postmortem idiopathic PD brains. Moreover, ATP13A2 colocalizes with α-syn in the LBs of sPD patients [53]. This evidence highlights the important role of ATP13A2 in dopamine neurons. The intricate association between ATP13A2 and PD was meticulously explored and described in previous reviews [51, 54].

To date, multiple ATP13A2 mutations (c.1597G > A, c.35C > T, c.2236G > A, c.3040G > A, c.844A > T, c.746C > T, c.1346G > A, and c.2939G > A) have been found to be involved in early-onset PD (onset < 40 years). These missense mutations in the ATP13A2 gene result in ATP13A2 dysfunction and impaired targeting of ATP13A2 to lysosomes [55]. Mutant ATP13A2 causes several lysosomal alterations, including diminished proteolytic processing of lysosomal enzymes, impaired lysosomal acidification, decreased lysosomal-mediated clearance of autophagosomes (APs), and reduced degradation of lysosomal substrates. Analogously, lysosomal dysfunction was observed in ATP13A2-knockdown dopaminergic cell lines. Supplementation of ATP13A2 in ATP13A2-mutant or ATP13A2-depleted cells can alleviate cell death and rescue lysosomal function [16].

The transport function of ATP13A2 in lysosomes is unclear. The polyamine spermidine (PA) is viewed as a potential substrate [56]. As physiologically vital polycations, PAs are tightly regulated by a complex interplay of export, import, degradation and synthesis. Extracellular PAs can bind to heparan sulfate proteoglycans in the plasma membrane and enter the cell via endocytosis before being transported into the cytosol by ATP13A2 [56]. Defective ATP13A2 results in decrease in cellular polyamine levels, which may intensify the disease phenotype because polyamines are scavengers of reactive oxygen species and heavy metals [58]. Moreover, ATP13A2 dysfunction inhibits late endolysosomal polyamine export and sensitizes cells to lysosomal disruption caused by exogenous polyamines [58]. Polyamine levels decrease in an age-dependent manner, whereas supplementation with polyamines increases lifespan in several model organisms [16, 57–61].

VPS35

Vacuolar protein sorting-associated protein 35 (VSP35) is involved in endosomal–lysosomal trafficking associated with autophagy [62]. The intricate nexus between VPS and PD has been diligently scrutinized in previous reviews [62–64]. VPS35 is a subunit of the retromer complex. The retromer complex includes two assembling subcomplexes: a sorting nexin (SNX) dimer and the cargo recognition VPS26–VPS29–VPS35 trimer. The retromer complex binds to the cytosolic portion of endosomes and mediates the reverse transport of transmembrane cargo from endosomes to the TGN. After sorting on the TGN, proteins are targeted to different destinations. It is involved in a series of vital physiological processes, including the classification of acid hydrolases into lysosomes, apoptotic cell clearance, Wnt secretion, biological development, and other cellular activities [65].

Mutations in VPS35 lead to a rare form of autosomal dominant PD [66]. The p.D620N (c.1858G > A) mutation has been recognized as a novel case of familial PD [66]. Among patients with the VPS35 p.D620N mutation, the incidences of rigidity, bradykinesia, postural instability, and tremor were at least 80%, 91.4%, 60%, and 77.1%, respectively. Almost all patients respond well to levodopa treatment. VPS35 mutations result in inactivity of the retromer complex, which impairs the classification of acid hydrolases into lysosomes and Wnt secretion. Removal of the VPS35 gene in flies and mice causes increased Aβ levels, elevated β-secretase activity, synaptic dysfunctions, and memory deficits [66]. These pathological changes have also been observed in VPS35-deficient mice [67]. VPS35 is mislocated in the brains of PD patients and is found in LBs [64]. Interestingly, VPS35 levels are decreased in dopaminergic neurons in the SNpc in sPD patient brains. Many studies have shown that VPS35 is involved in α-syn clearance by mediating autophagy [65, 68]. VPS35 deficiency causes widespread accumulation of α-syn aggregates in the SNpc, accompanied by degeneration of dopaminergic neurons, a decrease in DA levels, locomotor behavior impairment, and alterations in lysosomal morphology in vivo [65]. In contrast, the overexpression of VPS35 alleviates the formation of α-syn aggregates, the loss of DA neurons, and astrocyte proliferation in a mouse model of PD [65]. Consistent with these findings, genetic ablation of VPS35 in Drosophila causes α-syn accumulation and aggregation [68]. These results indicate that endosomal dysfunction caused by VPS35 deficiency interferes with the ability of neurons to address the abnormal accumulation and aggregation of α-syn, thus intensifying the spread of PD pathology and α-syn pathology.

The cation-independent 6 mannose phosphate receptor (CI-MPR) and sortilin are recognized as VPS35 cargo proteins. They act as lysosomal hydrolase receptors to regulate the sorting of acid hydrolases, such as cathepsins, from the TGN to lysosomes [69]. The VPS35 p.D620N mutation cannot be used to sort CI-MPRs [62]. Therefore, VPS35 is involved in lysosomal function by sorting receptors for lysosomal hydrolases. By regulating the recruitment of the WASH complex and the trafficking of the ATG9a protein, VPS35 participates in macroautophagy. The WASH complex regulates the autophagic process of autophagosome development and endosome-to-cell surface recycling. The VPS35 p.D620N mutant induces defects in autophagosome formation by impairing WASH complex recruitment to endosomes [66]. ATG9a participates in the autophagic pathway and controls the interaction of LC3-positive compartments with autophagosomes. Moreover, VPS35 is essential for retrieving the receptor LAMP2A [65].

VPS35 has also been implicated in the sorting of retromer complex-mediated DMT1 (divalent metal transporter 1) [70]. DMT1 is an endogenous transporter of ferrous iron that carries endosomal iron to the cytoplasm and imports extracellular iron [70]. Increasing evidence shows that iron is related to the pathology of PD. Iron accumulation has been detected in the SNpc of PD patients and mouse models [71]. Interestingly, DMT1 is upregulated in the same region [72]. Decrease of VPS35 by RNA interference causes misorting of DMT1 to lysosomal membrane-associated protein 2 (LAMP2)-positive structures, where it might act as an iron transporter [73]. These results indicate the vital role of VPS35 in PD pathogenesis via retromer-mediated endosomal recycling of the iron transporter DMT1.

In summary, pathogenic mutations in PD-related genes are involved in endosomal trafficking, indicating that dopaminergic neurons in the SN are specifically susceptible to endosomal dysfunctions.

Lysosomal dysfunction may contribute to α-syn pathology

Cathepsins and α-syn pathology

Cathepsins have been reported to directly participate in the degradation of monomeric and aggregated α-syn (Fig. 1) [74]. The cathepsin family comprises a total of 15 proteases systematically classified into three distinct groups on the basis of their catalytic mechanisms: serine cathepsins (A and G), cysteine cathepsins (B, C, F, H, K, L, O, S, V, W, and X), and aspartic cathepsins (D and E) [74]. CTSD, CTSL, and CTSB are notably prevalent in the central nervous system (CNS) and are implicated in pivotal neuronal functions, including synaptic plasticity [74]. CTSD activity degrades membrane-bound α-syn monomers and fibrils, whereas CTSL and CTSB degrade free α-syn monomers and fibrils [75, 76]. Importantly, CTSB activity is negatively correlated with α-syn high-molecular-weight (hMW) species [77]. Interestingly, the incomplete degradation of α-syn monomers and fibrils by CTSB and CTSL results in the formation of truncated aggregation-prone C-termini [75, 76].Fig. 1 Lysosomal dysfunction in α-syn pathology. Mutant GCase or GCase knockdown leads to α-syn accumulation by three ways: (1) GlcCer directly promotes the transformation of physiological α-synuclein into insoluble forms; (2) GlcSph enhances α-syn inclusion formation; (3) decreased Cer impairs α-syn degradation. Moreover, decreased activation of cathepsins, GALC, and aSMase result in damage of α-syn degradation. Damaged CMV and macroautophagy also impair α-syn degradation. These damaged pathways eventually cause α-syn accumulation and aggregation

GCase and α-syn pathology

GCase is not directly involved in α-syn degradation, but reduced GCase availability and activity exacerbates accumulation and aggregation of α-syn by compromising its protein degradation capacity [24, 78, 79]. Furthermore, GCase knockdown enhances the formation of insoluble and soluble α-syn high molecular weight (hMW) species in Drosophila [80]. Moreover, the glucosylceramide (GlcCer, the GCase substrate) and glucosylceramide/ceramide (GlcCer/Cer, where Cer is the GCase product) ratios in red blood cells are positively correlated with the α-syn dimer/monomer ratio [81]. GlcCer directly promotes the transformation of physiological α-synuclein into insoluble forms in iPSCs derived from individuals with PD [72]. Intriguingly, this phenomenon was reversed by reducing the level of GlcCer [72]. Glucosylsphingosine (GlcSph) causes hippocampal dysfunction and a reduction in excitatory synaptic proteins [83]. Moreover, GlcSph enhances α-syn inclusion formation in the hippocampus [83]. As a consequence of GCase failure, the levels of Cer in the lysosomal and endosomal compartments decrease [82]. Considering that Cer binds to CTSD and drives its cleavage into a catalytically active form, reduced Cer may also reduce the capacity of the lysosome to degrade α-syn [77, 84]. Compared with those in controls, decreased Cer in plasma samples and in the anterior cingulate cortex of PD patients have been reported [85–87]. Carmofur enhances Cer by inhibiting acid ceramidase activity and reducing α-syn accumulation in GBA1-PD-derived dopaminergic neurons [88]. GCase activity can also modulate the aggregation propensity of α-syn through its effect on lipid membrane composition [89].

GALC, aSMase, and α-syn pathology

The other two enzymes, galactosylceramidase (GALC) and acid sphingomyelinase (aSMase), catalyze the production of Cer within the lysosome and are known to be susceptibility factors for PD and other α-synucleinopathies [90–92]. Catalyzing the decomposition of sphingomyelin into Cer and phosphorylcholine decreases the occurrence of aSMase in the blood 3.5–5.8 years earlier than in the absence of PD [93]. GALC can catalyze the hydrolysis of galactosylceramide and galactosylsphingosine. Compared with that in age-matched controls, the level of galactosylsphingosine in the cortex was elevated in PD patients [94]. Moreover, galactosylsphingosine intensifies α-syn aggregation in a dose-dependent manner [95].

ALP dysfunction and α-syn pathology

In addition to decrease in hydrolase activity, autophagic‒lysosomal pathway (ALP) dysfunction has also been shown to promote exocytosis and intercellular proliferation of α-syn aggregates. Blocking the ALP with bafilomycin A1 results in the accumulation of α-syn aggregates in primary cortical neurons and nonneuronal cells [96, 97]. Similarly, macroautophagy inhibition by 3-methyladenine results in increased α-syn in PC12 cells [98]. Rapamycin, an inhibitor of mTOR, can reduce α-syn accumulation [99]. These studies suggest that impaired autophagy plays an important role in the aggregation and dissemination of α-syn. Therefore, regulating lysosomal function may be an important strategy for alleviating PD.

Chaperone-mediated autophagy in α-syn pathology

α-Syn is closely linked to chaperone-mediated autophagy (CMA), a lysosomal degradation process in which substrates are delivered by a chaperone protein [100]. In CMA, substrates must possess a conserved recognition motif, such as KFERQ, or other structurally analogous sequences [100]. Interestingly, α-syn harbors the sequence 95VKKDQ99, which is specifically recognized by HSP70 and facilitates its translocation to the lysosomal surface, where it associates with LAMP2 for subsequent degradation. In neuronal cell lines and primary neurons, wild-type α-syn is subject to degradation via CMA. However, this process is markedly impaired in mutant forms of α-syn that lack the 95VKKDQ99 sequence [101]. Furthermore, the levels of CMA-associated HSP70 and LAMP2 are markedly decreased in the SNpc and amygdala of PD patients, suggesting that disruptions in CMA play a role in disease pathogenesis [15]. Additionally, the A53T mutant form of α-syn has a robust affinity for LAMP2, accompanied by the inhibition of CMA and compromised lysosomal degradation. In the early stages of PD, the decrease in LAMP2A levels is influenced by elevated α-syn levels, which occur even prior to the accumulation of α-syn itself [102]. These findings indicate that CMA dysfunction represents an early event in PD. CMA is also integral to the turnover of essential factors critical for cell survival. Myocyte enhancer factor 2D (MEF2D), a pivotal protein for neuronal longevity, is known to be degraded via CMA. Both wild-type and mutant forms of α-syn can impede the degradation of MEF2D, leading to aberrant MEF2D activity and subsequent neuronal apoptosis [103]. Furthermore, elevated levels of MEF2D have been observed in α-syn transgenic mice as well as in PD patients, indicating that the pathological accumulation of MEF2D, due to CMA impairment, may constitute a significant mechanism underlying PD pathogenesis [104]. Nitration and oxidation of α-syn moderately compromise CMA, whereas phosphorylation of α-syn and dopamine-mediated modifications entirely inhibit CMA-mediated degradation of α-syn [105]. In summary, excessive aggregation of α-syn is closely tied to autophagy; however, under certain conditions, α-syn can also impede autophagic processes. This paradoxical relationship is crucial in the progression of PD. Therefore, elucidating the molecular mechanisms by which α-syn modulates autophagy is essential for the development of small molecule compounds aimed at restoring autophagic function.

Lysosome-mediated lipid destabilization in α-syn pathology

The major mammalian subclasses of lipids encompass five categories: sphingolipids, fatty acyls, glycerolipids, sterol lipids, and glycerophospholipids. Lipids have a wide range of functions. They can act as nutrients, hormone precursors, essential components of membranes, and necessary signaling molecules. Gene mutation, oxidative stress, aging and excess nutrients all pose challenges to lipid homeostasis [106–109]. Hence, cells need a precise system to contend with toxic, oxidized, and excess lipids, ensuring the maintenance of lipid homeostasis. Lipid droplets derived from the ER serve as eukaryotic organelles dedicated to lipid storage. Compared with the hydrophobic core, which houses neutral lipids and an encompassing phospholipid monolayer, lipid droplets feature an outer layer equipped with membrane proteins facilitating contact with other organelles to facilitate lipid transfer [110]. The predominant membrane proteins are perilipins, adipophilin, and a tail-interacting protein of 47 kDa.

In addition to cytosolic lipolysis, lipid droplets can also selectively target the autophagy pathway and are degraded by lysosomal acid lipases to produce glycerol and free fatty acids [2]. This process of selective autophagy is called the lipophagy [110]. Its dysfunction or overload can cause disease. Perilipins take part in regulating lipophagy initiation and lipase access to the core of lipid droplets. Primarily, protein kinase A phosphorylates perilipins, after which the phosphorylated perilipins are degraded via the proteasome [110]. Alternatively, perilipins are degraded through the chaperone-mediated autophagy (CMA)-dependent pathway, in which perilipin is identified by the heat shock cognate protein HSPA8/Hsc70 and is subsequently transported to the lysosome with the help of cochaperones upon attachment to the lysosomal membrane receptor LAMP2a. The surface of patatin-like phospholipase domain containing 2 (PNPLA2) is subsequently exposed. Known as an adipocyte triglyceride lipase, PNPLA2 binds to LC3b through its LC3-interacting motif and attaches lipids droplet to the autophagosomal membrane, thereby initiating macroautophagy [110]. Thus, lysosomes play a crucial role in inhibiting lipidosis by degrading lipids through lipophagy.

Lipid accumulation occurs in cases of lysosomal dysfunction. LBs may be composed of multitudinous lipid droplets and dystrophic organelles [111]. This finding has caused considerable debate in this field, that is, whether PD is a proteinopathy or should be regarded as a lipidopathy [106]. Galactosylceramidase inactivation results in the accumulation of cytotoxic lipid psychosine [94], which has been demonstrated to promote the aggregation of α-syn in vitro [112]. Moreover, after exposure to polyunsaturated fatty acids such as linoleic acid and arachidonic acid, α-syn abnormally and rapidly aggregates [113]. These studies suggest that lipid dysregulation caused by lysosomal dysfunction promotes α-syn aggregation.

Perspective on the diagnostic and therapeutic value of lysosomal dysfunction in PD

Lysosomal proteins assist in the diagnosis of PD

sPD accounts for the vast majority of PD cases and is the common result of aging and detrimental environmental factors plus a susceptible genetic background [12]. Mounting evidence indicates a diminishing trend in lysosomal activity as a corollary of the aging process [2]. Importantly, the activities of several lysosomal enzymes are significantly altered in PD patien ts compared with controls (summarized in Table 2). The activities of GCase, α-galactosidase A (α-Gal A), and cathepsin-D (CTSD) are decreased in the CSF of sPD patients [75, 77, 84, 114–116]. Compared with that in controls and patients with Alzheimer’s disease (AD) or frontotemporal dementia, GCase activity is decreased in the CSF of Lewy-body dementia patients [117]. Reduced activity of GCase has been observed not only in CSF but also in dried blood spots [24, 78, 118, 119]. The activity and level of GCase in the SNpc and other brain regions of sPD and DLB patients are significantly decreased [24]. Furthermore, brain regions with decreased GCase activity also show increased α-syn accumulation [24, 26, 28, 79, 80, 120]. Compared with those in age-matched healthy controls, CTSD, LAMP1, and heat shock protein 73 are decreased in the dopaminergic neurons of PD patients. Significantly decreased CTSD and α-Gal A activities have been reported in the brains of PD patients in the early stage of disease [77]. CTSD has also been found to be involved in AD and Huntington’s disease [121]. Compared with those in controls, HSC70 and LAMP2A are downregulated in the SNpc and amygdala of sPD patients [15, 122]. Furthermore, lower LAMP2A levels are directly correlated with increased α-syn. In summary, lysosomal enzymes can be supplemented with other diagnostic tests to improve the accuracy of PD diagnosis.Table 2 CSF lysosomal enzymes as diagnostic biomarkers for PD

Enzymes	Changes in CSF of PD patients	Ref	
α-mannosidase	Reduced	[164]	
β-mannosidase	Reduced	[164]	
GCase	Reduced	[164]	
β-galactosidase	Increased	[165]	
β-hexosaminidase	Increased	[118, 165]	
cathepsin E	Increased	[165]	
α-fucosidas	Reduced	[165]	
β-glucocerebrosidase	Reduced	[118, 155]	
cathepsin D	Reduced	[118]	

Potential lysosomal therapeutic targets for PD

Therapeutic strategies targeting GBA1

Genetic and biochemical studies have shown that PD-related pathogenic GBA1 mutations result in loss-of-function of GCase activity. There are two main therapeutic strategies for mitigating the effects of reduced GCase activity: (1) small-molecule chaperones to promote GCase activity and (2) therapies to inhibit the accumulation of GlcCer by GCase inhibition (summarized in Table 3).Table 3 Therapeutic strategies targeting GBA1

Agent	Tarkets	Stage	Primary outcome	NCT No	Ref	
Ambroxol	Increaseing GCase activity	Preclinical	Increased LIMP-2 and saposin C levels	NA	[124]	
Preclinical	Decreased α-syn and phosphorylated α-syn levels	NA	[125]	
Preclinical	Reduced lysosomal substrate storage and α-syn levels in cell	NA	[126]	
Phase I	Increased GCase activity and reduced markers of oxidative stress	NA	[127]	
Phase IIa	Ambroxol detected in CSF

Increased CSF GCase protein levels

Increased CSF α-syn levels in patients

Improvement of motor function

	NCT02941822	[128]	
Phase II	Changes in ADAS-cog and the CGIC	NCT02914366	NA	
Phase II	Changes in MOCA score and cognitive status	NCT05287503	NA	
Phase III	Slowed progression	NCT05778617	NA	
Observational	NA (ongoing)	NCT04388969	NA	
Phase I/II	NA (ongoing)	NCT04405596	NA	
Phase IIa	NA (ongoing)	NCT04588285	NA	
NCGC607	Restoring GCase activity	Preclinical	Restored GCase activity and protein levels

Reduced glycolipid storage

	NA	[126]	
Isofagomine (AT2101)	Enhancing GCase activity	Preclinical	Improved motor and nonmotor function

Reduced neuroinflammation and α-synuclein aggregates,

	NA	[166]	
Phase I	Safety, tolerability	NCT00875160	NA	
Phase II	Safety, tolerability	NCT00813865	NA	
Phase II	Safety, tolerability	NCT00446550	NA	
Phase II	Safety, tolerability	NCT00433147	NA	
NCGC00188758	Enhancing GCase activity	Preclinical	Promoted clearance of pathological α-syn	NA	[129]	
LTI-291	Enhancing GCase activity	Phase I	Safety, tolerability	NA	[167]	
PR001 (LY3884961)/Prevail Therapeutics	Restoring GCase activity	Phase I/II	Safety, tolerability, immunogenicity	NCT04127578	NA	
NCT04411654	NA	
NCT05487599	NA	
GZ667161	GCS inhibition	Preclinical	Slowed the accumulation of hippocampal aggregates of α-syn, ubiquitin, and tau

Improved the associated memory deficits

	NA	[130]	
Benzoxazole 1	GCS inhibition	Preclinical	Rescued lysosomal deficits, α-syn pathology and neuron toxicity	NA	[131]	
Venglustat (GZ/SAR402671)	GCS inhibitor	Phase II	Reduction in CSF GlcCer

Safety, tolerability

	NCT02843035	[168]	
Phase II	Safety, tolerability

Resulting in an early deterioration in motor function

	NCT02906020	[132, 133]	
Miglustat	GCS inhibition	Marketed	Safety, tolerability	NA	[134, 169]	
Eliglustat	GCS inhibition	Phase I	Safety, tolerability	NCT01659944	[134, 135]	
Lucerastat	GCS inhibition	Preclinical	Improved neurological performance	NA	[136, 137]	
Genz-682452	Enhancing GCase activity	Preclinical	Reduced the GluCer and hexosylsphingosine substrates

Enhanced the clearance of pathological α-syn

	NA	[170]	
Phase I	Safety, tolerability	NCT01710826	NA	
Phase I	Safety, tolerability	NCT01674036	NA	
ADAS-Cog, Alzheimer’s Disease Assessment Scale-cognitive subscale, CGIC ADCS-Clinician’s Global Impression of Change, CSF cerebrospinal fluid, GCase glucocerebrosidase, MDS-UPDRS MDS-Unified Parkinson’s Disease Rating Scale, MOCA Montreal Cognitive Assessment, NA not available

Small-molecule chaperones that promote GCase activity

Ambroxol was identified as a GCase chaperone. Ambroxol treatment exhibited remarkable therapeutic efficacy in preclinical trials: it promoted GCase activity by increasing mRNA and protein levels [123], increasing LIMP-2 and saposin C levels [124], decreasing α-syn and phosphorylated α-syn levels [125], and reducing lysosomal substrate storage [126]. In clinical trials, ambroxol has shown good safety and tolerability profiles and good blood‒brain barrier permeability. In addition, reduced levels of oxidative stress markers have been observed in patients treated with ambroxol [127]. Furthermore, in an open-label clinical trial involving 17 patients with PD (ClinicalTrials.gov ID: NCT02941822), ambroxol administration induced an increase in CSF GCase and improved motor function [128]. A phase 3a, multicenter, randomized, double-blind, placebo-controlled trial (ClinicalTrials.gov ID: NCT05778617) revealed that ambroxol treatment alleviated symptoms. Two trials of ambroxol have also been conducted in DLB patients (ClinicalTrials.gov ID: NCT04405596; NCT04588285). Other compounds targeting GCase include NCGC00188758, which has been shown to promote the clearance of pathological α-syn in iPSCs derived from PD [129], and NCGC607, which has been shown to restore GCase activity and protein levels and reduce glycolipid storage in iPSC-derived macrophages and dopaminergic neurons [126].

Therapies to inhibit the accumulation of GlcCer via GCase inhibition

GlcCer accumulation has been suggested to be a pathogenic mechanism of PD in GBA1 mutation carriers. Strategies for reducing GlcCer via GCase inhibition have also been reported. The brain-penetrating GCS inhibitor GZ667161 was proven to slow the accumulation of hippocampal aggregates of α-syn, ubiquitin, and tau and improve the associated memory deficits in synucleinopathy models [130]. Studies have shown that benzoxazole 1 rescues lysosomal deficits, α-syn pathology and neuronal toxicity [131]. These promising findings promoted the implementation of a phase 2, multicenter, randomized, double-blinded, placebo-controlled trial testing the effect of venglustat (GZ/SAR402671) in PD patients carrying GBA1 variants (ClinicalTrials.gov ID: NCT02906020). Administration of venglustat dose-dependently reduced CSF GlcCer levels. However, an initial worsening of motor function was observed [132, 133]. Subsequent advancements in the development of venglustat for GBA1-related PD have been halted. Other GCase chaperones, including miglustat, eliglustat, and lucerastat, have also been found to improve neurological performance [134–137].

Therapeutic strategies targeting LRRK2

Genetic and biochemical evidence underscores that pathogenic mutations associated with PD, notably the G2019S mutation and its variants in LRRK2, lead to a detrimental gain-of-function increase in LRRK2 kinase activity. In light of this pathogenic elevation in kinase function, ongoing therapeutic strategies for LRRK2-related PD are predominantly centered around the development and utilization of LRRK2 kinase inhibitors (summarized in Table 4).Table 4 Therapeutic strategies targeting LRRK2

Agent	Stage	Primary outcome	NCT No	Ref	
GZD-824	Preclinical	NA	NA	[171]	
EB-42168	Preclinical	NA	NA	[172]	
MLi-2	Preclinical	Chronic in-diet dosing with MLi-2 does not attenuate the behavioral phenotype in in MitoPark mice	NA	[139, 140]	
Preclinical	No change in motor phenotypes, pathological α-synuclein accumulation or neuron loss	NA	[173]	
PF-06447475	Preclinical	Protecting against nigral dopamine cell loss in MPTP mouse modle	NA	[141]	
PF-06685360	Preclinical	Increasing α-syn overlap with glutamatergic, cortico-striatal terminals, and dopaminergic nigral-striatal presynaptic terminals	NA	[142]	
LRRK2-in-1	Preclinical	An activation of the autophagic pathway	NA	[174]	
DNL201 (GNE-0877)	Phase I	well tolerated without serious adverse events	NCT04551534	[143]	
Phase I	Patients with mild to moderate PD	NCT03710707	[143]	
DNL151 (BIIB122)	Phase III	Early-stage PD participants with specific LRRK2 genetic variants	NCT05418673	[143]	
Phase I	PD patients	NCT04056689	NA	
Phase I	Healthy volunteers	NCT04557800	NA	
Phase I	Healthy volunteers	NCT05005338	NA	
Phase IIb	Early-stage PD patients	NCT05348785	NA	
Phase I	Healthy volunteers	NCT05119790	NA	
BIIB094 (ASO)	Phase I	evaluate the safety and tolerability	NCT03976349	[175]	
WXWH0226	Phase I	Healthy volunteers	CXHL2000520	NA	
NEU-723	Phase I	Healthy volunteers	NCT05633745	NA	

Small-molecule inhibitors targeting LRRK2 kinase activity are under investigation. A druggable compound should have commendable oral bioavailability, the capacity to permeate the blood‒brain barrier, and selectivity toward the kinase [138]. Cis-2,6-dimethyl-4-(6-(5-(1-methylcyclopropoxy)-1H-indazol-3-yl) pyrimidin-4-yl) morpholine (MLi-2) is a selective LRRK2 kinase inhibitor. However, MLi-2 reportedly does not attenuate the behavioral phenotype in MitoPark mice or pathological α-syn accumulation or neuron loss [139, 140]. PF-06447475 protected against nigral dopaminergic neuronal loss in an MPTP mouse model [141]. Moreover, PF-06685360 was found to increase the overlap of α-syn with glutamatergic and corticostriatal terminals and with dopaminergic nigral–striatal presynaptic terminals [142]. However, additional preclinical and clinical trials are needed to demonstrate the effectiveness of these small molecule compounds in the treatment of PD.

Four LRRK2 kinase inhibitors (DNL201, WXWH0226, NEU-723, and BIIB122) and one antisense oligonucleotide (ASO) (BIIB-094) are undergoing clinical trials (summarized in Table 4). DNL201 (GNE-0877) was assessed in a phase Ia study involving 122 healthy volunteers, during which favorable outcomes were demonstrated. Notably, an investigation revealed that DNL201 was well tolerated and not associated with serious adverse events [143]. A randomized, placebo-controlled phase 1b clinical trial in patients with mild to moderate PD with and without LRRK2 mutations is ongoing to assess its safety (ClinicalTrials.gov ID NCT03710707). RNA therapeutics are also under evaluation. Most studies have focused on RNA interference (RNAi) and antisense oligonucleotide (ASO) approaches. ASOs can inhibit RNA translation or regulate pre-mRNA maturation by splicing correction and reduce protein levels by targeting specific transcripts. Studies have shown that ASOs targeting LRRK2 can ameliorate α-syn aggregate formation in primary neurons and in mice treated with α-syn-preformed fibrils (PFFs) [144]. Moreover, LRRK2-ASO has been shown to ameliorate ER stress, promote neurite outgrowth, and decrease LRRK2 levels [145]. Strikingly, because of their good safety, efficacy and pharmacokinetics, ASOs provide a potential strategy for PD treatment without causing peripheral adverse effects.

Therapeutic strategies targeting other lysosomal components

Given the pivotal role of lysosomes and autophagy in the pathogenesis of PD, a variety of compounds targeting lysosomes are under investigation in animal models and clinical trials (summarized in Table 5). Trehalose is a disaccharide that regulates the activity of TFEB and activates autophagy processes. It has been proven to have therapeutic effects in vivo and in vitro [99, 146–150]. Trehalose inhibits lysosomal enlargement and the formation of massive aggregates in primary neurons. Moreover, the oral administration of trehalose decreases the aggregation and accumulation of α-syn in the SNpc, alleviates motor impairment, and reduces the loss of dopaminergic neurons in rats o overexpressressing A53T α-syn and in mice injected with MPTP [99]. However, the safety and effectiveness of trehalose in PD patients need further verification. As a key regulator of lysosomal biogenesis, TFEB is another vital therapeutic target for PD [149]. It has been reported that the activation and overexpression of TFEB alleviate the formation of α-syn inclusions and the loss of TH-positive neurons. Rapamycin and Rp analogs (CCI-779, RAD001 and AP23573) have been identified as inhibitors of mTORC1. Studies have reported that rapamycin and Rp analogs can improve motor function and reduce cell death by decreasing phospho-Ser129 α-syn levels and mitochondrial dysfunction [151]. Nilotinib, an inhibitor of Abelson tyrosine kinase (c-Abl), has been used to test the effect of Beclin-1-mediated autophagic α-syn clearance [152]. Nilotinib can reverse the loss of dopamine neurons and improve motor behavior via the autophagic degradation of a-synuclein in Parkinson’s disease models [152]. The results showed that nilotinib is potentially effective at mitigating motor and nonmotor symptoms in PD and DLB patients [153, 154].Table 5 Therapeutic strategies targeting others lysosomal components

Agent	Target	Stage	Primary outcome	Ref	
Trehalose	Activity of TFEB	Preclinical	Decreased aggregation and accumulation of α-syn

Alleviated motor impairment

Reduced loss of dopaminergic neurons

	[99]	
Reduced striatal dopaminergic deficits	[146]	
Reversed α-syn aggregation

Enhanced autophagy

	[147]	
Rapamycin and Rp analogs (CCI-779, RAD001 and AP23573)	Inhibitors of mTOR C1	Preclinical	Decreased phospho-Ser129 α-syn levels	[151]	
Reduced cell death	[176]	
Improved motor function

Reduced synaptic injury

	[177]	
Reduced mitochondrial dysfunction	[178]	
Nilotinib	Tyrosine kinase inhibitor	Preclinical	Reduced α-syn levels,

Suppressed DA neuronal loss

Improved motor deficits in mice

	[152]	
Phase II	The efficacy data trending in the negative direction indicate that nilotinib should not be further tested in PD	[179]	
Metformin	AMPK	Preclinical	Decreased cell death	[180]	
Reduced phospho-Ser129 α-syn levels	[181]	
AICAR	AMPK	Preclinical	Decreased cell death	[180]	
Resveratrol	AMPK	Preclinical	Promoted α-syn clearance	[182]	
KYP-2047	Beclin-1	Preclinical	Decreased oligomeric α-syn

Increased striatal DA levels

	[183]	
Isorhynchophylline	Beclin-1	Preclinical	Promoted α-syn clearance	[184]	
Reduced α-syn accumulation	[185]	
Acidic Nanoparticles	Lysosome	Preclinical	Restoration of lysosomal function

Reduced DA cell loss

	[186]	

Conclusions and future perspectives

Here we summarize the evidence demonstrating the relationship between lysosomal dysfunction and PD pathogenesis. Given that lysosomes play a central role in waste elimination and signal transduction, their dysfunction may lead to devastating consequences. The dysregulation of lysosomal function attributable to the aging process may constitute a fundamental etiological factor in sPD (Fig. 2). Gene mutations related to lysosomes, including GBA1, LRRK2, and VPS35, play a pathogenic role in both familial and sPD. However, the causal link between these mutations and α-syn aggregation is still unclear. Moreover, altered levels of lysosomal proteins, such as GCase and CTSD, in CSF and plasma have emerged as promising biomarkers for PD. GCase activity was 0.51 mU/ml in the CSF of PD patients and 0.78 mU/ml in the control group [155]. Moreover, CTSD-specific activity was lower in PD patients than in controls ( – 21%) [118]. However, lysosomal enzyme activity alone cannot discriminate between PD patients and patients with other degenerative diseases. A range of biomarkers, including a conformational and/or post-translated form of α-syn, mitochondrial dysfunction, inflammation, and other pathological proteins in PD, are needed to achieve the unique ability, sensitivity, and specificity to meet diagnostic criteria.Fig. 2 Lysosomal dysfunction contributes to the pathogenesis of PD. Genetic mutations, notably in pivotal genes such as GBA1 and LRRK2, in conjunction with diminished activity of lysosomal enzymes such as glucocerebrosidase (GCase), cathepsins, and galactosylceramidase (GALC), synergistically contribute to a state of lysosomal dysfunction. Lysosomal dysregulation prompts the accumulation of impaired mitochondria and lipids within the cellular cytoplasm. α-Syn, which is primarily subjected to degradation within the lysosomal milieu, faces compromised degradation due to lysosomal dysfunction. Consequently, α-syn accumulation and aggregation ensue. Furthermore, the byproducts of lysosomal damage precipitate the increase in α-syn levels, fostering its aggregation. Ultimately, insoluble aggregates form within the cytoplasm, precipitating neurodegeneration. The image was created with BioRender.com, with permission

Lysosomal damage plays a critical role in the pathogenesis of PD. Generalized lysosomal impairment is intimately associated with the failure to degrade α-syn aggregates. Nonetheless, the question of whether specific factors arising from lysosomal dysfunction can elucidate the selective aggregation of α-syn in PD remains unresolved. More research is needed to focus on this area in the future.

Moreover, elucidation of the correlation between lysosomal dysfunction and PD has yielded fresh perspectives on the pathogenic mechanisms that underlie PD, paving the way for innovative therapeutic strategies. A diverse array of small-molecule compounds has been formulated to modulate lysosomal function. Caution is paramount when investigating lysosomal activation or inhibition owing to the variability in lysosomal activity across different organs or tissues. Moreover, lysosomal activity can be irregularly heightened or diminished within specific organs or tissues, as well as within individual lysosomes of the same cell. Therefore, biodistribution studies conducted in vivo are imperative to prevent the undue accumulation of pharmaceutical agents in healthy tissues or organs. Ensuring safety is of utmost importance, particularly concerning the use of drugs intended as lysosome modulators for specific lysosomal disorders, to guard against inadvertently exacerbating susceptibility to other diseases. Further investigations are warranted to ascertain the safety, efficacy, and potential therapeutic applications of these compounds.

Acknowledgements

Not applicable.

Author contributions

Lijun Dai drafted and critically revised the work. Miao Liu, Wei Ke, and Liam Chen performed the literature search. Miao Liu and Xin Fang helped draw the charts during the revision phase of the article. Zhentao Zhang had the idea for the article. All the authors commented on previous versions of the manuscript. All the authors read and approved the final manuscript.

Funding

This work was supported by grants from the Innovative Research Groups of Hubei Province (2022CFA026), the National Natural Science Foundation of China (No. 82271447, 823B2026), the National Key Research and Development Program of China (2019YFE0115900), and the Project for Academic and Technical Leaders of Major Disciplines in Jiangxi Province (20213BCJL22049).

Data availability

Not applicable.

Declarations

Competing interests

The authors have no relevant financial or non-financial interests to disclose. The authors report no declarations of interest.

Consent to participate

Not applicable.

Consent to publish

Not applicable.

Ethics approval

Not applicable.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Kalia LV Lang AE Parkinson’s disease Lancet 2015 386 896 912 10.1016/S0140-6736(14)61393-3 25904081
Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386:896–912. 10.1016/S0140-6736(14)61393-325904081 10.1016/S0140-6736(14)61393-3
2. Aman Y Schmauck-Medina T Hansen M Autophagy in healthy aging and disease Nat Aging 2021 10.1038/s43587-021-00098-4 34901876
Aman Y, Schmauck-Medina T, Hansen M et al (2021) Autophagy in healthy aging and disease. Nat Aging. 10.1038/s43587-021-00098-434901876 10.1038/s43587-021-00098-4
3. Erskine D Koss D Korolchuk VI Lipids, lysosomes and mitochondria: insights into Lewy body formation from rare monogenic disorders Acta Neuropathol 2021 141 511 526 10.1007/s00401-021-02266-7 33515275
Erskine D, Koss D, Korolchuk VI et al (2021) Lipids, lysosomes and mitochondria: insights into Lewy body formation from rare monogenic disorders. Acta Neuropathol 141:511–526. 10.1007/s00401-021-02266-733515275 10.1007/s00401-021-02266-7
4. Udayar V Chen Y Sidransky E Jagasia R Lysosomal dysfunction in neurodegeneration: emerging concepts and methods Trends Neurosci 2022 45 184 199 10.1016/j.tins.2021.12.004 35034773
Udayar V, Chen Y, Sidransky E, Jagasia R (2022) Lysosomal dysfunction in neurodegeneration: emerging concepts and methods. Trends Neurosci 45:184–199. 10.1016/j.tins.2021.12.00435034773 10.1016/j.tins.2021.12.004
5. Lawrence RE Zoncu R The lysosome as a cellular centre for signalling, metabolism and quality control Nat Cell Biol 2019 21 133 142 10.1038/s41556-018-0244-7 30602725
Lawrence RE, Zoncu R (2019) The lysosome as a cellular centre for signalling, metabolism and quality control. Nat Cell Biol 21:133–142. 10.1038/s41556-018-0244-730602725 10.1038/s41556-018-0244-7
6. Wallings RL Humble SW Ward ME Wade-Martins R Lysosomal dysfunction at the centre of Parkinson’s disease and frontotemporal dementia/amyotrophic lateral sclerosis Trends Neurosci 2019 42 899 912 10.1016/j.tins.2019.10.002 31704179
Wallings RL, Humble SW, Ward ME, Wade-Martins R (2019) Lysosomal dysfunction at the centre of Parkinson’s disease and frontotemporal dementia/amyotrophic lateral sclerosis. Trends Neurosci 42:899–912. 10.1016/j.tins.2019.10.00231704179 10.1016/j.tins.2019.10.002
7. Parnetti L Gaetani L Eusebi P CSF and blood biomarkers for Parkinson’s disease Lancet Neurol 2019 18 573 586 10.1016/S1474-4422(19)30024-9 30981640
Parnetti L, Gaetani L, Eusebi P et al (2019) CSF and blood biomarkers for Parkinson’s disease. Lancet Neurol 18:573–586. 10.1016/S1474-4422(19)30024-930981640 10.1016/S1474-4422(19)30024-9
8. Ballabio A Bonifacino JS Lysosomes as dynamic regulators of cell and organismal homeostasis Nat Rev Mol Cell Biol 2020 21 101 118 10.1038/s41580-019-0185-4 31768005
Ballabio A, Bonifacino JS (2020) Lysosomes as dynamic regulators of cell and organismal homeostasis. Nat Rev Mol Cell Biol 21:101–118. 10.1038/s41580-019-0185-431768005 10.1038/s41580-019-0185-4
9. Settembre C Perera RM Lysosomes as coordinators of cellular catabolism, metabolic signalling and organ physiology Nat Rev Mol Cell Biol 2023 10.1038/s41580-023-00676-x 38001393
Settembre C, Perera RM (2023) Lysosomes as coordinators of cellular catabolism, metabolic signalling and organ physiology. Nat Rev Mol Cell Biol. 10.1038/s41580-023-00676-x38001393 10.1038/s41580-023-00676-x
10. Mizushima N Autophagy: process and function Genes Dev 2007 21 2861 2873 10.1101/gad.1599207 18006683
Mizushima N (2007) Autophagy: process and function. Genes Dev 21:2861–2873. 10.1101/gad.159920718006683 10.1101/gad.1599207
11. Settembre C Fraldi A Jahreiss L A block of autophagy in lysosomal storage disorders Hum Mol Genet 2008 17 119 129 10.1093/hmg/ddm289 17913701
Settembre C, Fraldi A, Jahreiss L et al (2008) A block of autophagy in lysosomal storage disorders. Hum Mol Genet 17:119–129. 10.1093/hmg/ddm28917913701 10.1093/hmg/ddm289
12. Navarro-Romero A Montpeyó M Martinez-Vicente M The emerging role of the lysosome in Parkinson’s disease Cells 2020 9 2399 10.3390/cells9112399 33147750
Navarro-Romero A, Montpeyó M, Martinez-Vicente M (2020) The emerging role of the lysosome in Parkinson’s disease. Cells 9:2399. 10.3390/cells911239933147750 10.3390/cells9112399
13. Yang J Wu X Song Y Recent advances in novel mutation genes of Parkinson’s disease J Neurol 2023 270 3723 3732 10.1007/s00415-023-11781-4 37222843
Yang J, Wu X, Song Y (2023) Recent advances in novel mutation genes of Parkinson’s disease. J Neurol 270:3723–3732. 10.1007/s00415-023-11781-437222843 10.1007/s00415-023-11781-4
14. Xilouri M Brekk OR Stefanis L Autophagy and alpha-synuclein: relevance to Parkinson’s disease and related synucleopathies Mov Disord 2016 31 178 192 10.1002/mds.26477 26813776
Xilouri M, Brekk OR, Stefanis L (2016) Autophagy and alpha-synuclein: relevance to Parkinson’s disease and related synucleopathies. Mov Disord 31:178–192. 10.1002/mds.2647726813776 10.1002/mds.26477
15. Chu Y Dodiya H Aebischer P Alterations in lysosomal and proteasomal markers in Parkinson’s disease: relationship to alpha-synuclein inclusions Neurobiol Dis 2009 35 385 398 10.1016/j.nbd.2009.05.023 19505575
Chu Y, Dodiya H, Aebischer P et al (2009) Alterations in lysosomal and proteasomal markers in Parkinson’s disease: relationship to alpha-synuclein inclusions. Neurobiol Dis 35:385–398. 10.1016/j.nbd.2009.05.02319505575 10.1016/j.nbd.2009.05.023
16. Dehay B Ramirez A Martinez-Vicente M Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration Proc Natl Acad Sci USA 2012 109 9611 9616 10.1073/pnas.1112368109 22647602
Dehay B, Ramirez A, Martinez-Vicente M et al (2012) Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc Natl Acad Sci USA 109:9611–9616. 10.1073/pnas.111236810922647602 10.1073/pnas.1112368109
17. Moors TE Paciotti S Ingrassia A Characterization of brain lysosomal activities in GBA-related and sporadic Parkinson’s disease and dementia with lewy bodies Mol Neurobiol 2019 56 2 1344 1355 10.1007/s12035-018-1090-0 29948939
Moors TE, Paciotti S, Ingrassia A et al (2019) Characterization of brain lysosomal activities in GBA-related and sporadic Parkinson’s disease and dementia with lewy bodies. Mol Neurobiol 56(2):1344–1355. 10.1007/s12035-018-1090-029948939 10.1007/s12035-018-1090-0
18. Yun SP Kim D Kim S α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism Mol Neurodegener 2018 13 1 1 10.1186/s13024-017-0233-5 29310663
Yun SP, Kim D, Kim S et al (2018) α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. Mol Neurodegener 13(1):129310663 10.1186/s13024-017-0233-5
19. Ryan E Seehra G Sharma P Sidransky E GBA1-associated parkinsonism: new insights and therapeutic opportunities Curr Opin Neurol 2019 32 589 596 10.1097/WCO.0000000000000715 31188151
Ryan E, Seehra G, Sharma P, Sidransky E (2019) GBA1-associated parkinsonism: new insights and therapeutic opportunities. Curr Opin Neurol 32:589–596. 10.1097/WCO.000000000000071531188151 10.1097/WCO.0000000000000715
20. Farfel-Becker T Do J Tayebi N Sidransky E Can GBA1-associated Parkinson disease be modeled in the mouse? Trends Neurosci 2019 42 631 643 10.1016/j.tins.2019.05.010 31288942
Farfel-Becker T, Do J, Tayebi N, Sidransky E (2019) Can GBA1-associated Parkinson disease be modeled in the mouse? Trends Neurosci 42:631–643. 10.1016/j.tins.2019.05.01031288942 10.1016/j.tins.2019.05.010
21. Burbulla LF Krainc D The role of dopamine in the pathogenesis of GBA1-linked Parkinson’s disease Neurobiol Dis 2019 132 104545 10.1016/j.nbd.2019.104545 31351996
Burbulla LF, Krainc D (2019) The role of dopamine in the pathogenesis of GBA1-linked Parkinson’s disease. Neurobiol Dis 132:104545. 10.1016/j.nbd.2019.10454531351996 10.1016/j.nbd.2019.104545
22. Gan-Or Z Liong C Alcalay RN GBA-associated Parkinson’s Disease and Other synucleinopathies Curr Neurol Neurosci Rep 2018 18 44 10.1007/s11910-018-0860-4 29884970
Gan-Or Z, Liong C, Alcalay RN (2018) GBA-associated Parkinson’s Disease and Other synucleinopathies. Curr Neurol Neurosci Rep 18:44. 10.1007/s11910-018-0860-429884970 10.1007/s11910-018-0860-4
23. Chiasserini D Paciotti S Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies Mol Neurodegener 2015 10.1186/s13024-015-0010-2 25881142
Chiasserini D, Paciotti S et al (2015) Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies. Mol Neurodegener. 10.1186/s13024-015-0010-225881142 10.1186/s13024-015-0010-2
24. Alcalay RN Levy OA Waters CH Glucocerebrosidase activity in Parkinson’s disease with and without GBA mutations Brain 2015 10.1093/brain/awv179 26117366
Alcalay RN, Levy OA, Waters CH et al (2015) Glucocerebrosidase activity in Parkinson’s disease with and without GBA mutations. Brain. 10.1093/brain/awv17926117366 10.1093/brain/awv179
25. Blandini F Cilia R Cerri S Glucocerebrosidase mutations and synucleinopathies: toward a model of precision medicine Mov Disord 2019 34 9 21 10.1002/mds.27583 30589955
Blandini F, Cilia R, Cerri S et al (2019) Glucocerebrosidase mutations and synucleinopathies: toward a model of precision medicine. Mov Disord 34:9–21. 10.1002/mds.2758330589955 10.1002/mds.27583
26. Rocha EM Smith GA Park E Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons Neurobiol Dis 2015 82 495 503 10.1016/j.nbd.2015.09.009 26392287
Rocha EM, Smith GA, Park E et al (2015) Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons. Neurobiol Dis 82:495–503. 10.1016/j.nbd.2015.09.00926392287 10.1016/j.nbd.2015.09.009
27. Cullen V Sardi SP Ng J Acid β-glucosidase mutants linked to gaucher disease, parkinson disease, and lewy body dementia alter α-synuclein processing Ann Neurol 2011 69 940 953 10.1002/ana.22400 21472771
Cullen V, Sardi SP, Ng J et al (2011) Acid β-glucosidase mutants linked to gaucher disease, parkinson disease, and lewy body dementia alter α-synuclein processing. Ann Neurol 69:940–953. 10.1002/ana.2240021472771 10.1002/ana.22400
28. Murphy KE Gysbers AM Abbott SK Reduced glucocerebrosidase is associated with increased -synuclein in sporadic Parkinson’s disease Brain 2014 137 834 848 10.1093/brain/awt367 24477431
Murphy KE, Gysbers AM, Abbott SK et al (2014) Reduced glucocerebrosidase is associated with increased -synuclein in sporadic Parkinson’s disease. Brain 137:834–848. 10.1093/brain/awt36724477431 10.1093/brain/awt367
29. Tolosa E Vila M Klein C Rascol O LRRK2 in Parkinson disease: challenges of clinical trials Nat Rev Neurol 2020 16 97 107 10.1038/s41582-019-0301-2 31980808
Tolosa E, Vila M, Klein C, Rascol O (2020) LRRK2 in Parkinson disease: challenges of clinical trials. Nat Rev Neurol 16:97–107. 10.1038/s41582-019-0301-231980808 10.1038/s41582-019-0301-2
30. Martin S Federico D Dhekne HS Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis Elife 2017 10.7554/eLife.31012 29239722
Martin S, Federico D, Dhekne HS et al (2017) Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis. Elife. 10.7554/eLife.3101229239722 10.7554/eLife.31012
31. Schreij AM, Chaineau M, Ruan W, et al (2015) LRRK2 localizes to endosomes and interacts with clathrin-light chains to limit Rac1 activation. EMBO Reports 16:79–86. 10.15252/embr.201438714
32. Bonet L Beilina A Williamson CD LRRK2 mediates tubulation and vesicle sorting from lysosomes Sci Adv 2020 6 eabb2454 10.1126/sciadv.abb2454 33177079
Bonet L, Beilina A, Williamson CD et al (2020) LRRK2 mediates tubulation and vesicle sorting from lysosomes. Sci Adv 6:eabb2454. 10.1126/sciadv.abb245433177079 10.1126/sciadv.abb2454
33. Komori T Kuwahara T An update on the interplay between LRRK2, Rab GTPases and Parkinson’s disease Biomolecules 2023 13 1645 10.3390/biom13111645 38002327
Komori T, Kuwahara T (2023) An update on the interplay between LRRK2, Rab GTPases and Parkinson’s disease. Biomolecules 13:1645. 10.3390/biom1311164538002327 10.3390/biom13111645
34. Pang SY-Y Lo RCN Ho PW-L LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson’s disease Transl Neurodegener 2022 11 5 10.1186/s40035-022-00281-6 35101134
Pang SY-Y, Lo RCN, Ho PW-L et al (2022) LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson’s disease. Transl Neurodegener 11:5. 10.1186/s40035-022-00281-635101134 10.1186/s40035-022-00281-6
35. Tong Y Yamaguchi H Giaime E Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice Proc Natl Acad Sci USA 2010 107 9879 9884 10.1073/pnas.1004676107 20457918
Tong Y, Yamaguchi H, Giaime E et al (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci USA 107:9879–9884. 10.1073/pnas.100467610720457918 10.1073/pnas.1004676107
36. Herzig MC Kolly C Persohn E LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice Hum Mol Genet 2011 20 4209 4223 10.1093/hmg/ddr348 21828077
Herzig MC, Kolly C, Persohn E et al (2011) LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet 20:4209–4223. 10.1093/hmg/ddr34821828077 10.1093/hmg/ddr348
37. Schapansky J Nardozzi JD Felizia F LaVoie MJ Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy Hum Mol Genet 2014 23 4201 4214 10.1093/hmg/ddu138 24682598
Schapansky J, Nardozzi JD, Felizia F, LaVoie MJ (2014) Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy. Hum Mol Genet 23:4201–4214. 10.1093/hmg/ddu13824682598 10.1093/hmg/ddu138
38. Manzoni C Mamais A Dihanich S Inhibition of LRRK2 kinase activity stimulates macroautophagy Biochim Biophys Acta 2013 1833 2900 2910 10.1016/j.bbamcr.2013.07.020 23916833
Manzoni C, Mamais A, Dihanich S et al (2013) Inhibition of LRRK2 kinase activity stimulates macroautophagy. Biochim Biophys Acta 1833:2900–2910. 10.1016/j.bbamcr.2013.07.02023916833 10.1016/j.bbamcr.2013.07.020
39. Manzoni C Mamais A Roosen DA mTOR independent regulation of macroautophagy by leucine Rich Repeat kinase 2 via beclin-1 Sci Rep 2016 6 35106 10.1038/srep35106 27731364
Manzoni C, Mamais A, Roosen DA et al (2016) mTOR independent regulation of macroautophagy by leucine Rich Repeat kinase 2 via beclin-1. Sci Rep 6:35106. 10.1038/srep3510627731364 10.1038/srep35106
40. Tong Y Giaime E Yamaguchi H Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway Mol Neurodegener 2012 7 2 10.1186/1750-1326-7-2 22230652
Tong Y, Giaime E, Yamaguchi H et al (2012) Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol Neurodegener 7:2. 10.1186/1750-1326-7-222230652 10.1186/1750-1326-7-2
41. Rocha EM Miranda B Castro S LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson’s disease Neurobiol Dis 2019 134 104626 10.1016/j.nbd.2019.104626 31618685
Rocha EM, Miranda B, Castro S et al (2019) LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson’s disease. Neurobiol Dis 134:104626. 10.1016/j.nbd.2019.10462631618685 10.1016/j.nbd.2019.104626
42. Jin YH Hyejung K Inhwa G An early endosome regulator, Rab5b, is an LRRK2 kinase substrate J Biochem 2015 157 485 495 10.1093/jb/mvv005 25605758
Jin YH, Hyejung K, Inhwa G et al (2015) An early endosome regulator, Rab5b, is an LRRK2 kinase substrate. J Biochem 157:485–495. 10.1093/jb/mvv00525605758 10.1093/jb/mvv005
43. Eguchi T Kuwahara T Sakurai M LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis Proc Natl Acad Sci USA 2018 115 E9115 E9124 10.1073/pnas.1812196115 30209220
Eguchi T, Kuwahara T, Sakurai M et al (2018) LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis. Proc Natl Acad Sci USA 115:E9115–E9124. 10.1073/pnas.181219611530209220 10.1073/pnas.1812196115
44. Jinn S Blauwendraat C Toolan D Functionalization of the TMEM175 p. M393T variant as a risk factor for Parkinson disease Hum Mol Genet 2019 28 3244 3254 10.1093/hmg/ddz136 31261387
Jinn S, Blauwendraat C, Toolan D et al (2019) Functionalization of the TMEM175 p. M393T variant as a risk factor for Parkinson disease. Hum Mol Genet 28:3244–3254. 10.1093/hmg/ddz13631261387 10.1093/hmg/ddz136
45. Houlden H Singleton AB The genetics and neuropathology of Parkinson’s disease Acta Neuropathol 2012 124 325 338 10.1007/s00401-012-1013-5 22806825
Houlden H, Singleton AB (2012) The genetics and neuropathology of Parkinson’s disease. Acta Neuropathol 124:325–338. 10.1007/s00401-012-1013-522806825 10.1007/s00401-012-1013-5
46. Krohn L Öztürk TN Vanderperre B Genetic, structural, and functional evidence link TMEM175 to synucleinopathies Ann Neurol 2020 87 139 153 10.1002/ana.25629 31658403
Krohn L, Öztürk TN, Vanderperre B et al (2020) Genetic, structural, and functional evidence link TMEM175 to synucleinopathies. Ann Neurol 87:139–153. 10.1002/ana.2562931658403 10.1002/ana.25629
47. Wu L Lin Y Song J TMEM175: a lysosomal ion channel associated with neurological diseases Neurobiol Dis 2023 185 106244 10.1016/j.nbd.2023.106244 37524211
Wu L, Lin Y, Song J et al (2023) TMEM175: a lysosomal ion channel associated with neurological diseases. Neurobiol Dis 185:106244. 10.1016/j.nbd.2023.10624437524211 10.1016/j.nbd.2023.106244
48. Cang C Aranda K Seo Y TMEM175 is an organelle K (+) channel regulating lysosomal function Cell 2015 162 1101 1112 10.1016/j.cell.2015.08.002 26317472
Cang C, Aranda K, Seo Y et al (2015) TMEM175 is an organelle K (+) channel regulating lysosomal function. Cell 162:1101–1112. 10.1016/j.cell.2015.08.00226317472 10.1016/j.cell.2015.08.002
49. Jinn S Drolet RE Cramer PE TMEM175 deficiency impairs lysosomal and mitochondrial function and increases α-synuclein aggregation Proc Natl Acad Sci USA 2017 114 2389 2394 10.1073/pnas.1616332114 28193887
Jinn S, Drolet RE, Cramer PE et al (2017) TMEM175 deficiency impairs lysosomal and mitochondrial function and increases α-synuclein aggregation. Proc Natl Acad Sci USA 114:2389–2394. 10.1073/pnas.161633211428193887 10.1073/pnas.1616332114
50. Tang T Jian B Liu Z Transmembrane protein 175, a lysosomal ion channel related to Parkinson’s disease Biomolecules 2023 13 802 10.3390/biom13050802 37238672
Tang T, Jian B, Liu Z (2023) Transmembrane protein 175, a lysosomal ion channel related to Parkinson’s disease. Biomolecules 13:802. 10.3390/biom1305080237238672 10.3390/biom13050802
51. Park J-S Blair NF Sue CM The role of ATP13A2 in Parkinson’s disease: clinical phenotypes and molecular mechanisms Mov Disord 2015 30 770 779 10.1002/mds.26243 25900096
Park J-S, Blair NF, Sue CM (2015) The role of ATP13A2 in Parkinson’s disease: clinical phenotypes and molecular mechanisms. Mov Disord 30:770–779. 10.1002/mds.2624325900096 10.1002/mds.26243
52. Bento CF Ashkenazi A Jimenez-Sanchez M Rubinsztein DC The Parkinson’s disease-associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway Nat Commun 2016 7 11803 10.1038/ncomms11803 27278822
Bento CF, Ashkenazi A, Jimenez-Sanchez M, Rubinsztein DC (2016) The Parkinson’s disease-associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway. Nat Commun 7:11803. 10.1038/ncomms1180327278822 10.1038/ncomms11803
53. Tillinghast J Drury S Bowser D Structural mechanisms for gating and ion selectivity of the human polyamine transporter ATP13A2 Mol Cell 2021 81 4650 4662.e4 10.1016/j.molcel.2021.10.002 34715014
Tillinghast J, Drury S, Bowser D et al (2021) Structural mechanisms for gating and ion selectivity of the human polyamine transporter ATP13A2. Mol Cell 81:4650-4662.e4. 10.1016/j.molcel.2021.10.00234715014 10.1016/j.molcel.2021.10.002
54. Zhang F Wu Z Long F The Roles of ATP13A2 gene mutations leading to abnormal aggregation of α-synuclein in Parkinson’s disease Front Cell Neurosci 2022 16 927682 10.3389/fncel.2022.927682 35875356
Zhang F, Wu Z, Long F et al (2022) The Roles of ATP13A2 gene mutations leading to abnormal aggregation of α-synuclein in Parkinson’s disease. Front Cell Neurosci 16:927682. 10.3389/fncel.2022.92768235875356 10.3389/fncel.2022.927682
55. Dehay B Martinez-Vicente M Ramirez A Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove Autophagy 2012 8 1389 1391 10.4161/auto.21011 22885599
Dehay B, Martinez-Vicente M, Ramirez A et al (2012) Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove. Autophagy 8:1389–1391. 10.4161/auto.2101122885599 10.4161/auto.21011
56. Madeo F Eisenberg T Pietrocola F Kroemer G Spermidine in health and disease Science 2018 359 eaan2788 10.1126/science.aan2788 29371440
Madeo F, Eisenberg T, Pietrocola F, Kroemer G (2018) Spermidine in health and disease. Science 359:eaan278829371440 10.1126/science.aan2788
57. Ramirez A Heimbach A Gründemann J Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase Nat Genet 2006 38 1184 1191 10.1038/ng1884 16964263
Ramirez A, Heimbach A, Gründemann J et al (2006) Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38:1184–1191. 10.1038/ng188416964263 10.1038/ng1884
58. Vrijsen S Besora-Casals L van Veen S ATP13A2-mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress Proc Natl Acad Sci USA 2020 117 31198 31207 10.1073/pnas.1922342117 33229544
Vrijsen S, Besora-Casals L, van Veen S et al (2020) ATP13A2-mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress. Proc Natl Acad Sci USA 117:31198–31207. 10.1073/pnas.192234211733229544 10.1073/pnas.1922342117
59. van Veen S Martin S Van den Haute C ATP13A2 deficiency disrupts lysosomal polyamine export Nature 2020 578 419 424 10.1038/s41586-020-1968-7 31996848
van Veen S, Martin S, Van den Haute C et al (2020) ATP13A2 deficiency disrupts lysosomal polyamine export. Nature 578:419–424. 10.1038/s41586-020-1968-731996848 10.1038/s41586-020-1968-7
60. Murphy KE Cottle L Gysbers AM ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies Acta Neuropathol Commun 2013 1 11 10.1186/2051-5960-1-11 24252509
Murphy KE, Cottle L, Gysbers AM et al (2013) ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. Acta Neuropathol Commun 1:11. 10.1186/2051-5960-1-1124252509 10.1186/2051-5960-1-11
61. Holemans T Sørensen DM van Veen S A lipid switch unlocks Parkinson’s disease-associated ATP13A2 Proc Natl Acad Sci USA 2015 112 9040 9045 10.1073/pnas.1508220112 26134396
Holemans T, Sørensen DM, van Veen S et al (2015) A lipid switch unlocks Parkinson’s disease-associated ATP13A2. Proc Natl Acad Sci USA 112:9040–9045. 10.1073/pnas.150822011226134396 10.1073/pnas.1508220112
62. Deng H Gao K Jankovic J The VPS35 gene and Parkinson’s disease Mov Disord 2013 28 569 575 10.1002/mds.25430 23536430
Deng H, Gao K, Jankovic J (2013) The VPS35 gene and Parkinson’s disease. Mov Disord 28:569–575. 10.1002/mds.2543023536430 10.1002/mds.25430
63. Cutillo G Simon DK Eleuteri S VPS35 and the mitochondria: connecting the dots in Parkinson’s disease pathophysiology Neurobiol Dis 2020 145 105056 10.1016/j.nbd.2020.105056 32853677
Cutillo G, Simon DK, Eleuteri S (2020) VPS35 and the mitochondria: connecting the dots in Parkinson’s disease pathophysiology. Neurobiol Dis 145:105056. 10.1016/j.nbd.2020.10505632853677 10.1016/j.nbd.2020.105056
64. Eleuteri S Albanese A VPS35-based approach: a potential innovative treatment in Parkinson’s disease Front Neurol 2019 10 1272 10.3389/fneur.2019.01272 31920908
Eleuteri S, Albanese A (2019) VPS35-based approach: a potential innovative treatment in Parkinson’s disease. Front Neurol 10:1272. 10.3389/fneur.2019.0127231920908 10.3389/fneur.2019.01272
65. Tang FL Erion JR Yun T VPS35 in dopamine neurons is required for endosome-to-golgi retrieval of Lamp2a, a receptor of chaperone-mediated autophagy that is critical for α-synuclein degradation and prevention of pathogenesis of Parkinson’s disease J Neurosci 2015 35 10613 10628 10.1523/JNEUROSCI.0042-15.2015 26203154
Tang FL, Erion JR, Yun T et al (2015) VPS35 in dopamine neurons is required for endosome-to-golgi retrieval of Lamp2a, a receptor of chaperone-mediated autophagy that is critical for α-synuclein degradation and prevention of pathogenesis of Parkinson’s disease. J Neurosci 35:10613–10628. 10.1523/JNEUROSCI.0042-15.201526203154 10.1523/JNEUROSCI.0042-15.2015
66. Zavodszky E Seaman MNJ Moreau K Mutation in VPS35 associated with Parkinson’s disease impairs WASH complex association and inhibits autophagy Nat Commun 2014 5 3828 10.1038/ncomms4828 24819384
Zavodszky E, Seaman MNJ, Moreau K et al (2014) Mutation in VPS35 associated with Parkinson’s disease impairs WASH complex association and inhibits autophagy. Nat Commun 5:3828. 10.1038/ncomms482824819384 10.1038/ncomms4828
67. Wen L Tang F-L Hong Y VPS35 haploinsufficiency increases Alzheimer’s disease neuropathology J Cell Biol 2011 195 765 779 10.1083/jcb.201105109 22105352
Wen L, Tang F-L, Hong Y et al (2011) VPS35 haploinsufficiency increases Alzheimer’s disease neuropathology. J Cell Biol 195:765–779. 10.1083/jcb.20110510922105352 10.1083/jcb.201105109
68. Miura E Hasegawa T Konno M VPS35 dysfunction impairs lysosomal degradation of α-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson’s disease Neurobiol Dis 2014 71 1 13 10.1016/j.nbd.2014.07.014 25107340
Miura E, Hasegawa T, Konno M et al (2014) VPS35 dysfunction impairs lysosomal degradation of α-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson’s disease. Neurobiol Dis 71:1–13. 10.1016/j.nbd.2014.07.01425107340 10.1016/j.nbd.2014.07.014
69. Braschi E Goyon V Zunino R Vps35 mediates vesicle transport between the mitochondria and peroxisomes Curr Biol 2010 20 1310 1315 10.1016/j.cub.2010.05.066 20619655
Braschi E, Goyon V, Zunino R et al (2010) Vps35 mediates vesicle transport between the mitochondria and peroxisomes. Curr Biol 20:1310–1315. 10.1016/j.cub.2010.05.06620619655 10.1016/j.cub.2010.05.066
70. Salazar J Mena N Hunot S Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson’s disease Proc Natl Acad Sci USA 2008 105 18578 18583 10.1073/pnas.0804373105 19011085
Salazar J, Mena N, Hunot S et al (2008) Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson’s disease. Proc Natl Acad Sci USA 105:18578–18583. 10.1073/pnas.080437310519011085 10.1073/pnas.0804373105
71. Benarroch EE Brain iron homeostasis and neurodegenerative disease Neurology 2009 72 1436 1440 10.1212/wnl.0b013e3181a26b30 19380704
Benarroch EE (2009) Brain iron homeostasis and neurodegenerative disease. Neurology 72:1436–1440. 10.1212/wnl.0b013e3181a26b3019380704 10.1212/wnl.0b013e3181a26b30
72. Zhang SZ Wang J Song N (2008) Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MPP+) -induced apoptosis in MES23.5 cells Neurobiol Aging. 2009 30 9 1466 1476 10.1016/j.cellbi.2008.01.057 18191877
Zhang SZ, Wang J, Song N et al (2009) (2008) Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MPP+) -induced apoptosis in MES23.5 cells. Neurobiol Aging. 30(9):1466–1476. 10.1016/j.cellbi.2008.01.05718191877 10.1016/j.cellbi.2008.01.057
73. Tabuchi M Yanatori I Kawai Y Kishi F Retromer-mediated direct sorting is required for proper endosomal recycling of the mammalian iron transporter DMT1 J Cell Sci 2010 123 756 766 10.1242/jcs.060574 20164305
Tabuchi M, Yanatori I, Kawai Y, Kishi F (2010) Retromer-mediated direct sorting is required for proper endosomal recycling of the mammalian iron transporter DMT1. J Cell Sci 123:756–766. 10.1242/jcs.06057420164305 10.1242/jcs.060574
74. Drobny A Prieto Huarcaya S Dobert J The role of lysosomal cathepsins in neurodegeneration: Mechanistic insights, diagnostic potential and therapeutic approaches Biochim Biophys Acta Mol Cell Res 2022 1869 119243 10.1016/j.bbamcr.2022.119243 35217144
Drobny A, Prieto Huarcaya S, Dobert J et al (2022) The role of lysosomal cathepsins in neurodegeneration: Mechanistic insights, diagnostic potential and therapeutic approaches. Biochim Biophys Acta Mol Cell Res 1869:119243. 10.1016/j.bbamcr.2022.11924335217144 10.1016/j.bbamcr.2022.119243
75. McGlinchey RO Lee JC Cysteine cathepsins are essential in lysosomal degradation of α-synuclein Proc Natl Acad Sci USA 2015 112 9322 9327 10.1073/pnas.1500937112 26170293
McGlinchey RO, Lee JC (2015) Cysteine cathepsins are essential in lysosomal degradation of α-synuclein. Proc Natl Acad Sci USA 112:9322–9327. 10.1073/pnas.150093711226170293 10.1073/pnas.1500937112
76. Sevlever D Jiang P Yen S-HC Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species Biochemistry 2008 47 9678 9687 10.1021/bi800699v 18702517
Sevlever D, Jiang P, Yen S-HC (2008) Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry 47:9678–9687. 10.1021/bi800699v18702517 10.1021/bi800699v
77. Liu F, Li X, Lu C, et al (2016) Ceramide activates lysosomal cathepsin B and cathepsin D to attenuate autophagy and induces ER stress to suppress myeloid-derived suppressor cells. Oncotarget 7:83907–83925. 10.18632/oncotarget.13438
78. Bae E-J Yang NY Lee C Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and α-synuclein aggregation Exp Mol Med 2015 47 e153 10.1038/emm.2014.128 25813221
Bae E-J, Yang NY, Lee C et al (2015) Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and α-synuclein aggregation. Exp Mol Med 47:e153. 10.1038/emm.2014.12825813221 10.1038/emm.2014.128
79. Suzuki M Fujikake N Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant α-synuclein and aggravates neurodegeneration in a Drosophila model of Parkinson’s disease Hum Mol Genet 2015 10.1093/hmg/ddv372 26362253
Suzuki M, Fujikake N et al (2015) Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant α-synuclein and aggravates neurodegeneration in a Drosophila model of Parkinson’s disease. Hum Mol Genet. 10.1093/hmg/ddv37226362253 10.1093/hmg/ddv372
80. Mazzulli J Xu YH Ying S Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies Cell 2011 146 37 52 10.1016/j.cell.2011.06.001 21700325
Mazzulli J, Xu YH, Ying S et al (2011) Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146:37–52. 10.1016/j.cell.2011.06.00121700325 10.1016/j.cell.2011.06.001
81. Moraitou M Dermentzaki G Dimitriou E α-Synuclein dimerization in erythrocytes of Gaucher disease patients: correlation with lipid abnormalities and oxidative stress Neurosci Lett 2016 613 1 5 10.1016/j.neulet.2015.12.013 26708635
Moraitou M, Dermentzaki G, Dimitriou E et al (2016) α-Synuclein dimerization in erythrocytes of Gaucher disease patients: correlation with lipid abnormalities and oxidative stress. Neurosci Lett 613:1–5. 10.1016/j.neulet.2015.12.01326708635 10.1016/j.neulet.2015.12.013
82. Zunke F Moise AC Belur NR Reversible conformational conversion of α-synuclein into toxic assemblies by glucosylceramide Neuron 2018 97 92 107.e10 10.1016/j.neuron.2017.12.012 29290548
Zunke F, Moise AC, Belur NR et al (2018) Reversible conformational conversion of α-synuclein into toxic assemblies by glucosylceramide. Neuron 97:92-107.e10. 10.1016/j.neuron.2017.12.01229290548 10.1016/j.neuron.2017.12.012
83. Mahoney-Crane CL Viswanathan M Russell D Neuronopathic GBA1L444P mutation accelerates glucosylsphingosine levels and formation of hippocampal alpha-synuclein inclusions J Neurosci 2023 43 501 521 10.1523/JNEUROSCI.0680-22.2022 36639889
Mahoney-Crane CL, Viswanathan M, Russell D et al (2023) Neuronopathic GBA1L444P mutation accelerates glucosylsphingosine levels and formation of hippocampal alpha-synuclein inclusions. J Neurosci 43:501–521. 10.1523/JNEUROSCI.0680-22.202236639889 10.1523/JNEUROSCI.0680-22.2022
84. Heinrich M Wickel M Schneider-Brachert W Cathepsin D targeted by acid sphingomyelinase-derived ceramide EMBO J 1999 18 5252 5263 10.1093/emboj/18.19.5252 10508159
Heinrich M, Wickel M, Schneider-Brachert W et al (1999) Cathepsin D targeted by acid sphingomyelinase-derived ceramide. EMBO J 18:5252–5263. 10.1093/emboj/18.19.525210508159 10.1093/emboj/18.19.5252
85. Mielke MM Maetzler W Haughey NJ Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson’s disease and associated with cognitive impairment: a pilot study PLoS One 2013 8 e73094 10.1371/journal.pone.0073094 24058461
Mielke MM, Maetzler W, Haughey NJ et al (2013) Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson’s disease and associated with cognitive impairment: a pilot study. PLoS One 8:e73094. 10.1371/journal.pone.007309424058461 10.1371/journal.pone.0073094
86. Kurz J Parnham MJ Geisslinger G Schiffmann S Ceramides as novel disease biomarkers Trends Mol Med 2019 25 20 32 10.1016/j.molmed.2018.10.009 30477968
Kurz J, Parnham MJ, Geisslinger G, Schiffmann S (2019) Ceramides as novel disease biomarkers. Trends Mol Med 25:20–32. 10.1016/j.molmed.2018.10.00930477968 10.1016/j.molmed.2018.10.009
87. Abbott SK Li H Muñoz SS Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson’s disease Mov Disord 2014 29 518 526 10.1002/mds.25729 24822250
Abbott SK, Li H, Muñoz SS et al (2014) Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson’s disease. Mov Disord 29:518–526. 10.1002/mds.2572924822250 10.1002/mds.25729
88. Kim MJ Jeon S Burbulla LF Krainc D Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function Hum Mol Genet 2018 27 1972 1988 10.1093/hmg/ddy105 29579237
Kim MJ, Jeon S, Burbulla LF, Krainc D (2018) Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function. Hum Mol Genet 27:1972–1988. 10.1093/hmg/ddy10529579237 10.1093/hmg/ddy105
89. Galvagnion C Marlet FR Cerri S Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation Brain 2022 145 1038 1051 10.1093/brain/awab371 35362022
Galvagnion C, Marlet FR, Cerri S et al (2022) Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation. Brain 145:1038–1051. 10.1093/brain/awab37135362022 10.1093/brain/awab371
90. Chang D Nalls MA Hallgrímsdóttir IB A meta-analysis of genome-wide association studies identifies 17 new Parkinson’s disease risk loci Nat Genet 2017 49 1511 1516 10.1038/ng.3955 28892059
Chang D, Nalls MA, Hallgrímsdóttir IB et al (2017) A meta-analysis of genome-wide association studies identifies 17 new Parkinson’s disease risk loci. Nat Genet 49:1511–1516. 10.1038/ng.395528892059 10.1038/ng.3955
91. Gan-Or Z Ozelius LJ Bar-Shira A The p. L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease Neurology 2013 80 1606 1610 10.1212/WNL.0b013e31828f180e 23535491
Gan-Or Z, Ozelius LJ, Bar-Shira A et al (2013) The p. L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease. Neurology 80:1606–1610. 10.1212/WNL.0b013e31828f180e23535491 10.1212/WNL.0b013e31828f180e
92. Dagan E Schlesinger I Ayoub M The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews Parkinsonism Relat Disord 2015 21 1067 1071 10.1016/j.parkreldis.2015.06.016 26169695
Dagan E, Schlesinger I, Ayoub M et al (2015) The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews. Parkinsonism Relat Disord 21:1067–1071. 10.1016/j.parkreldis.2015.06.01626169695 10.1016/j.parkreldis.2015.06.016
93. Alcalay RN Mallett V Vanderperre B SMPD1 mutations, activity, and α-synuclein accumulation in Parkinson’s disease Mov Disord 2019 34 526 535 10.1002/mds.27642 30788890
Alcalay RN, Mallett V, Vanderperre B et al (2019) SMPD1 mutations, activity, and α-synuclein accumulation in Parkinson’s disease. Mov Disord 34:526–535. 10.1002/mds.2764230788890 10.1002/mds.27642
94. Marshall MS Jakubauskas B Bogue W Analysis of age-related changes in psychosine metabolism in the human brain PLoS One 2018 13 e0193438 10.1371/journal.pone.0193438 29481565
Marshall MS, Jakubauskas B, Bogue W et al (2018) Analysis of age-related changes in psychosine metabolism in the human brain. PLoS One 13:e0193438. 10.1371/journal.pone.019343829481565 10.1371/journal.pone.0193438
95. Smith BR Santos MB Marshall MS Neuronal inclusions of α-synuclein contribute to the pathogenesis of Krabbe disease J Pathol 2014 232 509 521 10.1002/path.4328 24415155
Smith BR, Santos MB, Marshall MS et al (2014) Neuronal inclusions of α-synuclein contribute to the pathogenesis of Krabbe disease. J Pathol 232:509–521. 10.1002/path.432824415155 10.1002/path.4328
96. Webb JL Ravikumar B Atkins J α-Synuclein is degraded by both autophagy and the proteasome J Biol Chem 2003 278 25009 25013 10.1074/jbc.M300227200 12719433
Webb JL, Ravikumar B, Atkins J et al (2003) α-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 278:25009–25013. 10.1074/jbc.M30022720012719433 10.1074/jbc.M300227200
97. Klucken J Poehler A-M Ebrahimi-Fakhari D Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway Autophagy 2012 8 754 766 10.4161/auto.19371 22647715
Klucken J, Poehler A-M, Ebrahimi-Fakhari D et al (2012) Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway. Autophagy 8:754–766. 10.4161/auto.1937122647715 10.4161/auto.19371
98. Vogiatzi T Xilouri M Vekrellis K Stefanis L Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells J Biol Chem 2008 283 23542 23556 10.1074/jbc.M801992200 18566453
Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L (2008) Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem 283:23542–23556. 10.1074/jbc.M80199220018566453 10.1074/jbc.M801992200
99. Pupyshev AB Tikhonova MA Akopyan AA Therapeutic activation of autophagy by combined treatment with rapamycin and trehalose in a mouse MPTP-induced model of Parkinson’s disease Pharmacol Biochem Behav 2019 177 1 11 10.1016/j.pbb.2018.12.005 30582934
Pupyshev AB, Tikhonova MA, Akopyan AA et al (2019) Therapeutic activation of autophagy by combined treatment with rapamycin and trehalose in a mouse MPTP-induced model of Parkinson’s disease. Pharmacol Biochem Behav 177:1–11. 10.1016/j.pbb.2018.12.00530582934 10.1016/j.pbb.2018.12.005
100. Kaushik S Cuervo AM Chaperone-mediated autophagy: a unique way to enter the lysosome world Trends Cell Biol 2012 22 407 417 10.1016/j.tcb.2012.05.006 22748206
Kaushik S, Cuervo AM (2012) Chaperone-mediated autophagy: a unique way to enter the lysosome world. Trends Cell Biol 22:407–417. 10.1016/j.tcb.2012.05.00622748206 10.1016/j.tcb.2012.05.006
101. Cuervo AM Stefanis L Fredenburg R Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy Science 2004 305 1292 1295 10.1126/science.1101738 15333840
Cuervo AM, Stefanis L, Fredenburg R et al (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305:1292–1295. 10.1126/science.110173815333840 10.1126/science.1101738
102. Murphy KE Gysbers AM Abbott SK Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson’s disease Mov Disord 2015 30 1639 1647 10.1002/mds.26141 25594542
Murphy KE, Gysbers AM, Abbott SK et al (2015) Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson’s disease. Mov Disord 30:1639–1647. 10.1002/mds.2614125594542 10.1002/mds.26141
103. Yang Q Mao Z Dysregulation of autophagy and Parkinson’s disease: the MEF2D link Apoptosis 2010 15 1410 1414 10.1007/s10495-010-0475-y 20165919
Yang Q, Mao Z (2010) Dysregulation of autophagy and Parkinson’s disease: the MEF2D link. Apoptosis 15:1410–1414. 10.1007/s10495-010-0475-y20165919 10.1007/s10495-010-0475-y
104. Winslow AR Rubinsztein DC The Parkinson disease protein α-synuclein inhibits autophagy Autophagy 2011 7 429 431 10.4161/auto.7.4.14393 21157184
Winslow AR, Rubinsztein DC (2011) The Parkinson disease protein α-synuclein inhibits autophagy. Autophagy 7:429–431. 10.4161/auto.7.4.1439321157184 10.4161/auto.7.4.14393
105. Koga H Cuervo AM Chaperone-mediated autophagy dysfunction in the pathogenesis of neurodegeneration Neurobiol Dis 2011 43 29 37 10.1016/j.nbd.2010.07.006 20643207
Koga H, Cuervo AM (2011) Chaperone-mediated autophagy dysfunction in the pathogenesis of neurodegeneration. Neurobiol Dis 43:29–37. 10.1016/j.nbd.2010.07.00620643207 10.1016/j.nbd.2010.07.006
106. Fanning S Selkoe D Dettmer U Parkinson’s disease: proteinopathy or lipidopathy? Nat Publ Group 2020 10.1038/S41531-019-0103-7
Fanning S, Selkoe D, Dettmer U (2020) Parkinson’s disease: proteinopathy or lipidopathy? Nat Publ Group. 10.1038/S41531-019-0103-710.1038/S41531-019-0103-7
107. Hallett PJ Engelender S Isacson O Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson’s disease J Neuroinflammation 2019 16 153 10.1186/s12974-019-1532-2 31331333
Hallett PJ, Engelender S, Isacson O (2019) Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson’s disease. J Neuroinflammation 16:153. 10.1186/s12974-019-1532-231331333 10.1186/s12974-019-1532-2
108. Guedes LC Chan RB Gomes MA Serum lipid alterations in GBA-associated Parkinson’s disease Parkinsonism Relat Disord 2017 44 58 65 10.1016/j.parkreldis.2017.08.026 28890071
Guedes LC, Chan RB, Gomes MA et al (2017) Serum lipid alterations in GBA-associated Parkinson’s disease. Parkinsonism Relat Disord 44:58–65. 10.1016/j.parkreldis.2017.08.02628890071 10.1016/j.parkreldis.2017.08.026
109. Xicoy H Wieringa B Martens GJM The role of lipids in Parkinson’s disease Cells 2019 8 E27 10.3390/cells8010027
Xicoy H, Wieringa B, Martens GJM (2019) The role of lipids in Parkinson’s disease. Cells 8:E27. 10.3390/cells801002710.3390/cells8010027
110. Shin DW (2020) Lipophagy: Molecular Mechanisms and Implications in Metabolic Disorders. Mol Cells 43:686–693. 10.14348/molcells.2020.0046
111. Shahmoradian SH Lewis AJ Genoud C Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes Nat Neurosci 2019 22 1099 1109 10.1038/s41593-019-0423-2 31235907
Shahmoradian SH, Lewis AJ, Genoud C et al (2019) Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes. Nat Neurosci 22:1099–1109. 10.1038/s41593-019-0423-231235907 10.1038/s41593-019-0423-2
112. Suzuki K Iseki E Togo T Neuronal and glial accumulation of alpha- and beta-synucleins in human lipidoses Acta Neuropathol 2007 114 481 489 10.1007/s00401-007-0264-z 17653558
Suzuki K, Iseki E, Togo T et al (2007) Neuronal and glial accumulation of alpha- and beta-synucleins in human lipidoses. Acta Neuropathol 114:481–489. 10.1007/s00401-007-0264-z17653558 10.1007/s00401-007-0264-z
113. Ali A Holman AP Rodriguez A Elucidating the mechanisms of α-Synuclein-lipid interactions using site-directed mutagenesis Neurobiol Dis 2024 198 106553 10.1016/j.nbd.2024.106553 38839022
Ali A, Holman AP, Rodriguez A et al (2024) Elucidating the mechanisms of α-Synuclein-lipid interactions using site-directed mutagenesis. Neurobiol Dis 198:106553. 10.1016/j.nbd.2024.10655338839022 10.1016/j.nbd.2024.106553
114. Alcalay RN Wolf P Levy OA Alpha galactosidase A activity in Parkinson’s disease Neurobiol Dis 2018 112 85 90 10.1016/j.nbd.2018.01.012 29369793
Alcalay RN, Wolf P, Levy OA et al (2018) Alpha galactosidase A activity in Parkinson’s disease. Neurobiol Dis 112:85–90. 10.1016/j.nbd.2018.01.01229369793 10.1016/j.nbd.2018.01.012
115. Nelson MP Boutin M Tse TE The lysosomal enzyme alpha-Galactosidase A is deficient in Parkinson’s disease brain in association with the pathologic accumulation of alpha-synuclein Neurobiol Dis 2018 110 68 81 10.1016/j.nbd.2017.11.006 29196214
Nelson MP, Boutin M, Tse TE et al (2018) The lysosomal enzyme alpha-Galactosidase A is deficient in Parkinson’s disease brain in association with the pathologic accumulation of alpha-synuclein. Neurobiol Dis 110:68–81. 10.1016/j.nbd.2017.11.00629196214 10.1016/j.nbd.2017.11.006
116. Wu G Yan B Wang X Decreased activities of lysosomal acid alpha-D-galactosidase A in the leukocytes of sporadic Parkinson’s disease J Neurol Sci 2008 271 168 173 10.1016/j.jns.2008.04.011 18495164
Wu G, Yan B, Wang X et al (2008) Decreased activities of lysosomal acid alpha-D-galactosidase A in the leukocytes of sporadic Parkinson’s disease. J Neurol Sci 271:168–173. 10.1016/j.jns.2008.04.01118495164 10.1016/j.jns.2008.04.011
117. Parnetti L Balducci C Pierguidi L Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies Neurobiol Dis 2009 34 484 486 10.1016/j.nbd.2009.03.002 19303930
Parnetti L, Balducci C, Pierguidi L et al (2009) Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies. Neurobiol Dis 34:484–486. 10.1016/j.nbd.2009.03.00219303930 10.1016/j.nbd.2009.03.002
118. Parnetti L Paciotti S Eusebi P Cerebrospinal fluid β-glucocerebrosidase activity is reduced in Parkinson’s disease patients Mov Disord 2017 32 1423 1431 10.1002/mds.27136 28843015
Parnetti L, Paciotti S, Eusebi P et al (2017) Cerebrospinal fluid β-glucocerebrosidase activity is reduced in Parkinson’s disease patients. Mov Disord 32:1423–1431. 10.1002/mds.2713628843015 10.1002/mds.27136
119. Sardi SP Clarke J Viel C Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies Proc Natl Acad Sci USA 2013 110 3537 3542 10.1073/pnas.1220464110 23297226
Sardi SP, Clarke J, Viel C et al (2013) Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc Natl Acad Sci USA 110:3537–3542. 10.1073/pnas.122046411023297226 10.1073/pnas.1220464110
120. Abul K Dhanushkodi NR Ardah MT Silencing of glucocerebrosidase gene in Drosophila enhances the aggregation of Parkinson’s disease associated α-synuclein mutant A53T and affects locomotor activity Front Neurosci 2018 12 81 10.3389/fnins.2018.00081 29503608
Abul K, Dhanushkodi NR, Ardah MT et al (2018) Silencing of glucocerebrosidase gene in Drosophila enhances the aggregation of Parkinson’s disease associated α-synuclein mutant A53T and affects locomotor activity. Front Neurosci 12:81. 10.3389/fnins.2018.0008129503608 10.3389/fnins.2018.00081
121. Vidoni C Follo C Savino M The role of cathepsin D in the pathogenesis of human neurodegenerative disorders Med Res Rev 2016 36 845 870 10.1002/med.21394 27114232
Vidoni C, Follo C, Savino M et al (2016) The role of cathepsin D in the pathogenesis of human neurodegenerative disorders. Med Res Rev 36:845–870. 10.1002/med.2139427114232 10.1002/med.21394
122. Murphy KE Gysbers AM Abbott SK Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson’s disease Mov Disord Off J Mov Disord Soc 2015 30 1639 1647 10.1002/mds.26141
Murphy KE, Gysbers AM, Abbott SK et al (2015) Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson’s disease. Mov Disord Off J Mov Disord Soc 30:1639–1647. 10.1002/mds.2614110.1002/mds.26141
123. Magalhaes J Gegg ME Migdalska-Richards A Schapira AH Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons Sci Rep 2018 8 1385 10.1038/s41598-018-19479-8 29362387
Magalhaes J, Gegg ME, Migdalska-Richards A, Schapira AH (2018) Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons. Sci Rep 8:1385. 10.1038/s41598-018-19479-829362387 10.1038/s41598-018-19479-8
124. Ambrosi G Ghezzi C Zangaglia R Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson’s disease cells Neurobiol Dis 2015 82 235 242 10.1016/j.nbd.2015.06.008 26094596
Ambrosi G, Ghezzi C, Zangaglia R et al (2015) Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson’s disease cells. Neurobiol Dis 82:235–242. 10.1016/j.nbd.2015.06.00826094596 10.1016/j.nbd.2015.06.008
125. Migdalska-Richards A Daly L Bezard E Schapira AHV Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice Ann Neurol 2016 80 766 775 10.1002/ana.24790 27859541
Migdalska-Richards A, Daly L, Bezard E, Schapira AHV (2016) Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice. Ann Neurol 80:766–775. 10.1002/ana.2479027859541 10.1002/ana.24790
126. Aflaki E Borger DK Moaven N A new glucocerebrosidase chaperone reduces α-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and Parkinsonism J Neurosci 2016 36 7441 7452 10.1523/JNEUROSCI.0636-16.2016 27413154
Aflaki E, Borger DK, Moaven N et al (2016) A new glucocerebrosidase chaperone reduces α-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and Parkinsonism. J Neurosci 36:7441–7452. 10.1523/JNEUROSCI.0636-16.201627413154 10.1523/JNEUROSCI.0636-16.2016
127. McNeill A Magalhaes J Shen C Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells Brain 2014 137 1481 1495 10.1093/brain/awu020 24574503
McNeill A, Magalhaes J, Shen C et al (2014) Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 137:1481–1495. 10.1093/brain/awu02024574503 10.1093/brain/awu020
128. Mullin S Smith L Lee K Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations JAMA Neurol 2020 77 427 434 10.1001/jamaneurol.2019.4611 31930374
Mullin S, Smith L, Lee K et al (2020) Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations. JAMA Neurol 77:427–434. 10.1001/jamaneurol.2019.461131930374 10.1001/jamaneurol.2019.4611
129. Mazzulli JR Zunke F Tsunemi T Activation of β-Glucocerebrosidase reduces pathological α-synuclein and restores lysosomal function in Parkinson’s patient midbrain neurons J Neurosci 2016 36 7693 7706 10.1523/JNEUROSCI.0628-16.2016 27445146
Mazzulli JR, Zunke F, Tsunemi T et al (2016) Activation of β-Glucocerebrosidase reduces pathological α-synuclein and restores lysosomal function in Parkinson’s patient midbrain neurons. J Neurosci 36:7693–7706. 10.1523/JNEUROSCI.0628-16.201627445146 10.1523/JNEUROSCI.0628-16.2016
130. Sardi SP Viel C Clarke J Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models Proc Natl Acad Sci USA 2017 114 2699 2704 10.1073/pnas.1616152114 28223512
Sardi SP, Viel C, Clarke J et al (2017) Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. Proc Natl Acad Sci USA 114:2699–2704. 10.1073/pnas.161615211428223512 10.1073/pnas.1616152114
131. Cosden M Jinn S Yao L A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy Neurobiol Dis 2021 159 105507 10.1016/j.nbd.2021.105507 34509608
Cosden M, Jinn S, Yao L et al (2021) A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy. Neurobiol Dis 159:105507. 10.1016/j.nbd.2021.10550734509608 10.1016/j.nbd.2021.105507
132. Peterschmitt MJ Crawford NPS Gaemers SJM Pharmacokinetics, pharmacodynamics, safety, and tolerability of oral venglustat in healthy volunteers Clin Pharmacol Drug Dev 2021 10 86 98 10.1002/cpdd.865 32851809
Peterschmitt MJ, Crawford NPS, Gaemers SJM et al (2021) Pharmacokinetics, pharmacodynamics, safety, and tolerability of oral venglustat in healthy volunteers. Clin Pharmacol Drug Dev 10:86–98. 10.1002/cpdd.86532851809 10.1002/cpdd.865
133. Giladi N Alcalay RN Cutter G Safety and efficacy of venglustat in GBA1-associated Parkinson’s disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial Lancet Neurol 2023 22 661 671 10.1016/S1474-4422(23)00205-3 37479372
Giladi N, Alcalay RN, Cutter G et al (2023) Safety and efficacy of venglustat in GBA1-associated Parkinson’s disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 22:661–671. 10.1016/S1474-4422(23)00205-337479372 10.1016/S1474-4422(23)00205-3
134. Smid BE Ferraz MJ Verhoek M Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease Type 1 patients Orphanet J Rare Dis 2016 11 28 10.1186/s13023-016-0413-3 27008851
Smid BE, Ferraz MJ, Verhoek M et al (2016) Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease Type 1 patients. Orphanet J Rare Dis 11:28. 10.1186/s13023-016-0413-327008851 10.1186/s13023-016-0413-3
135. Mistry PK Lukina E Ben Turkia H Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease Type 1: The phase 3 ENGAGE trial Am J Hematol 2017 92 1170 1176 10.1002/ajh.24877 28762527
Mistry PK, Lukina E, Ben Turkia H et al (2017) Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease Type 1: The phase 3 ENGAGE trial. Am J Hematol 92:1170–1176. 10.1002/ajh.2487728762527 10.1002/ajh.24877
136. Guérard N Morand O Dingemanse J Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects Orphanet J Rare Dis 2017 12 9 10.1186/s13023-017-0565-9 28088251
Guérard N, Morand O, Dingemanse J (2017) Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects. Orphanet J Rare Dis 12:9. 10.1186/s13023-017-0565-928088251 10.1186/s13023-017-0565-9
137. Guérard N Oder D Nordbeck P Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with fabry disease on enzyme replacement Clin Pharmacol Ther 2018 103 703 711 10.1002/cpt.790 28699267
Guérard N, Oder D, Nordbeck P et al (2018) Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with fabry disease on enzyme replacement. Clin Pharmacol Ther 103:703–711. 10.1002/cpt.79028699267 10.1002/cpt.790
138. Hu J Zhang D Tian K Small-molecule LRRK2 inhibitors for PD therapy: current achievements and future perspectives Eur J Med Chem 2023 256 115475 10.1016/j.ejmech.2023.115475 37201428
Hu J, Zhang D, Tian K et al (2023) Small-molecule LRRK2 inhibitors for PD therapy: current achievements and future perspectives. Eur J Med Chem 256:115475. 10.1016/j.ejmech.2023.11547537201428 10.1016/j.ejmech.2023.115475
139. Kluss JH Mazza MC Li Y Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo Mol Neurodegener 2021 16 17 10.1186/s13024-021-00441-8 33741046
Kluss JH, Mazza MC, Li Y et al (2021) Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo. Mol Neurodegener 16:17. 10.1186/s13024-021-00441-833741046 10.1186/s13024-021-00441-8
140. Fell MJ Mirescu C Basu K MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition J Pharmacol Exp Ther 2015 355 397 409 10.1124/jpet.115.227587 26407721
Fell MJ, Mirescu C, Basu K et al (2015) MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition. J Pharmacol Exp Ther 355:397–409. 10.1124/jpet.115.22758726407721 10.1124/jpet.115.227587
141. Novello S Mercatelli D Albanese F In vivo susceptibility to energy failure Parkinsonism and LRRK2 kinase activity Neurobiol Dis 2022 162 105579 10.1016/j.nbd.2021.105579 34871735
Novello S, Mercatelli D, Albanese F et al (2022) In vivo susceptibility to energy failure Parkinsonism and LRRK2 kinase activity. Neurobiol Dis 162:105579. 10.1016/j.nbd.2021.10557934871735 10.1016/j.nbd.2021.105579
142. Brzozowski CF Hijaz BA Singh V Inhibition of LRRK2 kinase activity promotes anterograde axonal transport and presynaptic targeting of α-synuclein Acta Neuropathol Commun 2021 9 180 10.1186/s40478-021-01283-7 34749824
Brzozowski CF, Hijaz BA, Singh V et al (2021) Inhibition of LRRK2 kinase activity promotes anterograde axonal transport and presynaptic targeting of α-synuclein. Acta Neuropathol Commun 9:180. 10.1186/s40478-021-01283-734749824 10.1186/s40478-021-01283-7
143. Inc DT (2018) Denali therapeutics announces first patient dosed in phase 1b study of DNL201 for Parkinson’s disease. In: GlobeNewswire News Room. https://www.globenewswire.com/news-release/2018/12/10/1664447/0/en/Denali-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1b-Study-of-DNL201-for-Parkinson-s-Disease.html. Accessed 22 Dec 2023
144. Zhao HT John N Delic V LRRK2 antisense oligonucleotides ameliorate α-synuclein inclusion formation in a Parkinson’s disease mouse model Mol Ther Nucleic Acids 2017 8 508 519 10.1016/j.omtn.2017.08.002 28918051
Zhao HT, John N, Delic V et al (2017) LRRK2 antisense oligonucleotides ameliorate α-synuclein inclusion formation in a Parkinson’s disease mouse model. Mol Ther Nucleic Acids 8:508–519. 10.1016/j.omtn.2017.08.00228918051 10.1016/j.omtn.2017.08.002
145. Korecka JA Talbot S Osborn TM Neurite collapse and altered ER Ca2+ control in human Parkinson disease patient iPSC-derived neurons with LRRK2 G2019S mutation Stem Cell Reports 2018 12 29 41 10.1016/j.stemcr.2018.11.021 30595548
Korecka JA, Talbot S, Osborn TM et al (2018) Neurite collapse and altered ER Ca2+ control in human Parkinson disease patient iPSC-derived neurons with LRRK2 G2019S mutation. Stem Cell Reports 12:29–41. 10.1016/j.stemcr.2018.11.02130595548 10.1016/j.stemcr.2018.11.021
146. Howson PA Johnston TH Ravenscroft P Beneficial effects of trehalose on striatal dopaminergic deficits in rodent and primate models of synucleinopathy in Parkinson’s disease J Pharmacol Exp Ther 2019 369 364 374 10.1124/jpet.118.255695 30918068
Howson PA, Johnston TH, Ravenscroft P et al (2019) Beneficial effects of trehalose on striatal dopaminergic deficits in rodent and primate models of synucleinopathy in Parkinson’s disease. J Pharmacol Exp Ther 369:364–374. 10.1124/jpet.118.25569530918068 10.1124/jpet.118.255695
147. He Q Koprich JB Wang Y Treatment with trehalose prevents behavioral and neurochemical deficits produced in an AAV α-synuclein rat model of Parkinson’s disease Mol Neurobiol 2016 53 2258 2268 10.1007/s12035-015-9173-7 25972237
He Q, Koprich JB, Wang Y et al (2016) Treatment with trehalose prevents behavioral and neurochemical deficits produced in an AAV α-synuclein rat model of Parkinson’s disease. Mol Neurobiol 53:2258–2268. 10.1007/s12035-015-9173-725972237 10.1007/s12035-015-9173-7
148. Richards AB Krakowka S Dexter LB Trehalose: a review of properties, history of use and human tolerance, and results of multiple safety studies Food Chem Toxicol 2002 40 871 898 10.1016/s0278-6915(02)00011-x 12065209
Richards AB, Krakowka S, Dexter LB et al (2002) Trehalose: a review of properties, history of use and human tolerance, and results of multiple safety studies. Food Chem Toxicol 40:871–898. 10.1016/s0278-6915(02)00011-x12065209 10.1016/s0278-6915(02)00011-x
149. Rusmini P Cortese K Crippa V Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration Autophagy 2019 15 631 651 10.1080/15548627.2018.1535292 30335591
Rusmini P, Cortese K, Crippa V et al (2019) Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration. Autophagy 15:631–651. 10.1080/15548627.2018.153529230335591 10.1080/15548627.2018.1535292
150. Tanji K Miki Y Maruyama A Trehalose intake induces chaperone molecules along with autophagy in a mouse model of Lewy body disease Biochem Biophys Res Commun 2015 465 746 752 10.1016/j.bbrc.2015.08.076 26299928
Tanji K, Miki Y, Maruyama A et al (2015) Trehalose intake induces chaperone molecules along with autophagy in a mouse model of Lewy body disease. Biochem Biophys Res Commun 465:746–752. 10.1016/j.bbrc.2015.08.07626299928 10.1016/j.bbrc.2015.08.076
151. Crews L Spencer B Desplats P Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy PLoS One 2010 5 e9313 10.1371/journal.pone.0009313 20174468
Crews L, Spencer B, Desplats P et al (2010) Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One 5:e9313. 10.1371/journal.pone.000931320174468 10.1371/journal.pone.0009313
152. Hebron ML Lonskaya I Moussa CE-H Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson’s disease models Hum Mol Genet 2013 22 3315 3328 10.1093/hmg/ddt192 23666528
Hebron ML, Lonskaya I, Moussa CE-H (2013) Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson’s disease models. Hum Mol Genet 22:3315–3328. 10.1093/hmg/ddt19223666528 10.1093/hmg/ddt192
153. Pagan F Hebron M Valadez EH Nilotinib effects in Parkinson’s disease and dementia with Lewy bodies J Parkinsons Dis 2016 6 503 517 10.3233/JPD-160867 27434297
Pagan F, Hebron M, Valadez EH et al (2016) Nilotinib effects in Parkinson’s disease and dementia with Lewy bodies. J Parkinsons Dis 6:503–517. 10.3233/JPD-16086727434297 10.3233/JPD-160867
154. Pagan FL Hebron ML Wilmarth B Pharmacokinetics and pharmacodynamics of a single dose nilotinib in individuals with Parkinson’s disease Pharmacol Res Perspect 2019 7 e00470 10.1002/prp2.470 30906562
Pagan FL, Hebron ML, Wilmarth B et al (2019) Pharmacokinetics and pharmacodynamics of a single dose nilotinib in individuals with Parkinson’s disease. Pharmacol Res Perspect 7:e00470. 10.1002/prp2.47030906562 10.1002/prp2.470
155. Parnetti L Chiasserini D Persichetti E Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson’s disease Mov Disord 2014 29 1019 1027 10.1002/mds.25772 24436092
Parnetti L, Chiasserini D, Persichetti E et al (2014) Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson’s disease. Mov Disord 29:1019–1027. 10.1002/mds.2577224436092 10.1002/mds.25772
156. Li H Ham A Ma TC Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations Autophagy 2019 15 113 130 10.1080/15548627.2018.1509818 30160596
Li H, Ham A, Ma TC et al (2019) Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations. Autophagy 15:113–130. 10.1080/15548627.2018.150981830160596 10.1080/15548627.2018.1509818
157. Fernandes HJR Hartfield EM Christian HC ER stress and autophagic perturbations lead to elevated extracellular α-synuclein in GBA-N370S Parkinson’s iPSC-derived dopamine neurons Stem Cell Reports 2016 6 342 356 10.1016/j.stemcr.2016.01.013 26905200
Fernandes HJR, Hartfield EM, Christian HC et al (2016) ER stress and autophagic perturbations lead to elevated extracellular α-synuclein in GBA-N370S Parkinson’s iPSC-derived dopamine neurons. Stem Cell Reports 6:342–356. 10.1016/j.stemcr.2016.01.01326905200 10.1016/j.stemcr.2016.01.013
158. Mazzulli JR Xu Y-H Sun Y Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies Cell 2011 146 37 52 10.1016/j.cell.2011.06.001 21700325
Mazzulli JR, Xu Y-H, Sun Y et al (2011) Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146:37–52. 10.1016/j.cell.2011.06.00121700325 10.1016/j.cell.2011.06.001
159. Bravo-San Pedro JM Niso-Santano M Gómez-Sánchez R The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway Cell Mol Life Sci 2013 70 121 136 10.1007/s00018-012-1061-y 22773119
Bravo-San Pedro JM, Niso-Santano M, Gómez-Sánchez R et al (2013) The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway. Cell Mol Life Sci 70:121–136. 10.1007/s00018-012-1061-y22773119 10.1007/s00018-012-1061-y
160. Gómez-Suaga P Luzón-Toro B Churamani D Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP Hum Mol Genet 2012 21 511 525 10.1093/hmg/ddr481 22012985
Gómez-Suaga P, Luzón-Toro B, Churamani D et al (2012) Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum Mol Genet 21:511–525. 10.1093/hmg/ddr48122012985 10.1093/hmg/ddr481
161. Orenstein SJ Kuo S-H Tasset I Interplay of LRRK2 with chaperone-mediated autophagy Nat Neurosci 2013 16 394 406 10.1038/nn.3350 23455607
Orenstein SJ, Kuo S-H, Tasset I et al (2013) Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci 16:394–406. 10.1038/nn.335023455607 10.1038/nn.3350
162. Ho PW-L Leung C-T Liu H Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA) Autophagy 2020 16 347 370 10.1080/15548627.2019.1603545 30983487
Ho PW-L, Leung C-T, Liu H et al (2020) Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA). Autophagy 16:347–370. 10.1080/15548627.2019.160354530983487 10.1080/15548627.2019.1603545
163. Martin S Smolders S Van den Haute C Mutated ATP10B increases Parkinson’s disease risk by compromising lysosomal glucosylceramide export Acta Neuropathol 2020 139 1001 1024 10.1007/s00401-020-02145-7 32172343
Martin S, Smolders S, Van den Haute C et al (2020) Mutated ATP10B increases Parkinson’s disease risk by compromising lysosomal glucosylceramide export. Acta Neuropathol 139:1001–1024. 10.1007/s00401-020-02145-732172343 10.1007/s00401-020-02145-7
164. Balducci C Pierguidi L Persichetti E Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson’s disease Mov Disord 2007 22 1481 1484 10.1002/mds.21399 17546678
Balducci C, Pierguidi L, Persichetti E et al (2007) Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson’s disease. Mov Disord 22:1481–1484. 10.1002/mds.2139917546678 10.1002/mds.21399
165. van Dijk KD Persichetti E Chiasserini D Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson’s disease Mov Disord 2013 28 747 754 10.1002/mds.25495 23712522
van Dijk KD, Persichetti E, Chiasserini D et al (2013) Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson’s disease. Mov Disord 28:747–754. 10.1002/mds.2549523712522 10.1002/mds.25495
166. Richter F Fleming SM Watson M A GCase chaperone improves motor function in a mouse model of synucleinopathy Neurotherapeutics 2014 11 840 856 10.1007/s13311-014-0294-x 25037721
Richter F, Fleming SM, Watson M et al (2014) A GCase chaperone improves motor function in a mouse model of synucleinopathy. Neurotherapeutics 11:840–856. 10.1007/s13311-014-0294-x25037721 10.1007/s13311-014-0294-x
167. den Heijer JM Kruithof AC van Amerongen G A randomized single and multiple ascending dose study in healthy volunteers of LTI-291, a centrally penetrant glucocerebrosidase activator Br J Clin Pharmacol 2021 87 3561 3573 10.1111/bcp.14772 33576113
den Heijer JM, Kruithof AC, van Amerongen G et al (2021) A randomized single and multiple ascending dose study in healthy volunteers of LTI-291, a centrally penetrant glucocerebrosidase activator. Br J Clin Pharmacol 87:3561–3573. 10.1111/bcp.1477233576113 10.1111/bcp.14772
168. Schiffmann R Cox TM Dedieu J-F Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial Brain 2023 146 461 474 10.1093/brain/awac379 36256599
Schiffmann R, Cox TM, Dedieu J-F et al (2023) Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial. Brain 146:461–474. 10.1093/brain/awac37936256599 10.1093/brain/awac379
169. Pastores GM Barnett NL Kolodny EH An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment Clin Ther 2005 27 1215 1227 10.1016/j.clinthera.2005.08.004 16199246
Pastores GM, Barnett NL, Kolodny EH (2005) An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther 27:1215–1227. 10.1016/j.clinthera.2005.08.00416199246 10.1016/j.clinthera.2005.08.004
170. Marshall J Sun Y Bangari DS CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease Mol Ther 2016 24 1019 1029 10.1038/mt.2016.53 26948439
Marshall J, Sun Y, Bangari DS et al (2016) CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease. Mol Ther 24:1019–1029. 10.1038/mt.2016.5326948439 10.1038/mt.2016.53
171. Sanz Murillo M Villagran Suarez A Dederer V Inhibition of Parkinson’s disease-related LRRK2 by type I and type II kinase inhibitors: activity and structures Sci Adv 2023 9 eadk6191 10.1126/sciadv.adk6191 38039358
Sanz Murillo M, Villagran Suarez A, Dederer V et al (2023) Inhibition of Parkinson’s disease-related LRRK2 by type I and type II kinase inhibitors: activity and structures. Sci Adv 9:eadk6191. 10.1126/sciadv.adk619138039358 10.1126/sciadv.adk6191
172. Bright JM Carlisle HJ Toda AMA Differential inhibition of LRRK2 in Parkinson’s disease patient blood by a G2019S selective LRRK2 inhibitor Mov Disord 2021 36 1362 1371 10.1002/mds.28490 33836114
Bright JM, Carlisle HJ, Toda AMA et al (2021) Differential inhibition of LRRK2 in Parkinson’s disease patient blood by a G2019S selective LRRK2 inhibitor. Mov Disord 36:1362–1371. 10.1002/mds.2849033836114 10.1002/mds.28490
173. Henderson MX Sengupta M McGeary I LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice Acta Neuropathol Commun 2019 7 28 10.1186/s40478-019-0679-5 30808409
Henderson MX, Sengupta M, McGeary I et al (2019) LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice. Acta Neuropathol Commun 7:28. 10.1186/s40478-019-0679-530808409 10.1186/s40478-019-0679-5
174. Ruz C Alcantud JL Vives F Seventy-Two-Hour LRRK2 kinase activity inhibition increases lysosomal GBA expression in H4, a human neuroglioma cell line Int J Mol Sci 2022 23 6935 10.3390/ijms23136935 35805938
Ruz C, Alcantud JL, Vives F et al (2022) Seventy-Two-Hour LRRK2 kinase activity inhibition increases lysosomal GBA expression in H4, a human neuroglioma cell line. Int J Mol Sci 23:6935. 10.3390/ijms2313693535805938 10.3390/ijms23136935
175. Müller T DNL151, DNL201, and BIIB094: experimental agents for the treatment of Parkinson’s disease Expert Opin Investig Drugs 2023 32 787 792 10.1080/13543784.2023.2263357 37755071
Müller T (2023) DNL151, DNL201, and BIIB094: experimental agents for the treatment of Parkinson’s disease. Expert Opin Investig Drugs 32:787–792. 10.1080/13543784.2023.226335737755071 10.1080/13543784.2023.2263357
176. Malagelada C Jin ZH Jackson-Lewis V Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson’s disease J Neurosci 2010 30 1166 1175 10.1523/JNEUROSCI.3944-09.2010 20089925
Malagelada C, Jin ZH, Jackson-Lewis V et al (2010) Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson’s disease. J Neurosci 30:1166–1175. 10.1523/JNEUROSCI.3944-09.201020089925 10.1523/JNEUROSCI.3944-09.2010
177. Bai X Wey MC-Y Fernandez E Rapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathy Pathobiol Aging Age Relat Dis 2015 5 28743 10.3402/pba.v5.28743 26306821
Bai X, Wey MC-Y, Fernandez E et al (2015) Rapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathy. Pathobiol Aging Age Relat Dis 5:28743. 10.3402/pba.v5.2874326306821 10.3402/pba.v5.28743
178. Tain LS Mortiboys H Tao RN Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss Nat Neurosci 2009 12 1129 1135 10.1038/nn.2372 19684592
Tain LS, Mortiboys H, Tao RN et al (2009) Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat Neurosci 12:1129–1135. 10.1038/nn.237219684592 10.1038/nn.2372
179. Simuni T Fiske B Merchant K Efficacy of nilotinib in patients with moderately advanced parkinson disease: a randomized clinical trial JAMA Neurol 2021 78 312 320 10.1001/jamaneurol.2020.4725 33315105
Simuni T, Fiske B, Merchant K et al (2021) Efficacy of nilotinib in patients with moderately advanced parkinson disease: a randomized clinical trial. JAMA Neurol 78:312–320. 10.1001/jamaneurol.2020.472533315105 10.1001/jamaneurol.2020.4725
180. Ng C-H Guan MSH Koh C AMP kinase activation mitigates dopaminergic dysfunction and mitochondrial abnormalities in Drosophila models of Parkinson’s disease J Neurosci 2012 32 14311 14317 10.1523/JNEUROSCI.0499-12.2012 23055502
Ng C-H, Guan MSH, Koh C et al (2012) AMP kinase activation mitigates dopaminergic dysfunction and mitochondrial abnormalities in Drosophila models of Parkinson’s disease. J Neurosci 32:14311–14317. 10.1523/JNEUROSCI.0499-12.201223055502 10.1523/JNEUROSCI.0499-12.2012
181. Pérez-Revuelta BI Hettich MM Ciociaro A Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation Cell Death Dis 2014 5 e1209 10.1038/cddis.2014.175 24810045
Pérez-Revuelta BI, Hettich MM, Ciociaro A et al (2014) Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation. Cell Death Dis 5:e1209. 10.1038/cddis.2014.17524810045 10.1038/cddis.2014.175
182. Wu Y Li X Zhu JX Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson’s disease Neurosignals 2011 19 163 174 10.1159/000328516 21778691
Wu Y, Li X, Zhu JX et al (2011) Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson’s disease. Neurosignals 19:163–174. 10.1159/00032851621778691 10.1159/000328516
183. Savolainen MH Richie CT Harvey BK The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse Neurobiol Dis 2014 68 1 15 10.1016/j.nbd.2014.04.003 24746855
Savolainen MH, Richie CT, Harvey BK et al (2014) The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse. Neurobiol Dis 68:1–15. 10.1016/j.nbd.2014.04.00324746855 10.1016/j.nbd.2014.04.003
184. Lu J-H Tan J-Q Durairajan SSK Isorhynchophylline, a natural alkaloid, promotes the degradation of alpha-synuclein in neuronal cells via inducing autophagy Autophagy 2012 8 98 108 10.4161/auto.8.1.18313 22113202
Lu J-H, Tan J-Q, Durairajan SSK et al (2012) Isorhynchophylline, a natural alkaloid, promotes the degradation of alpha-synuclein in neuronal cells via inducing autophagy. Autophagy 8:98–108. 10.4161/auto.8.1.1831322113202 10.4161/auto.8.1.18313
185. Decressac M Mattsson B Weikop P TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity Proc Natl Acad Sci USA 2013 110 E1817 1826 10.1073/pnas.1305623110 23610405
Decressac M, Mattsson B, Weikop P et al (2013) TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc Natl Acad Sci USA 110:E1817-1826. 10.1073/pnas.130562311023610405 10.1073/pnas.1305623110
186. Bourdenx M Daniel J Genin E Nanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseases Autophagy 2016 12 472 483 10.1080/15548627.2015.1136769 26761717
Bourdenx M, Daniel J, Genin E et al (2016) Nanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseases. Autophagy 12:472–483. 10.1080/15548627.2015.113676926761717 10.1080/15548627.2015.1136769
